Epidemiology, comorbidity and clinical course of myasthenia gravis. A registry-based study by Andersen, Jintana Bunpan
Dissertation for the degree of philosophiae doctor (PhD)  
at the University of Bergen 
Dissertation date: 
(SLGHPLRORJ\FRPRUELGLW\DQGFOLQLFDO
FRXUVHRIP\DVWKHQLDJUDYLV
$UHJLVWU\EDVHGVWXG\
-LQWDQD%XQSDQ$QGHUVHQ

-DQXDU\QG
© Copyright Jintana Bunpan Andersen 
The material in this publication is protected by copyright law.  
 
Year: 2015 
Title: Epidemiology, comorbidity and clinical course of myasthenia gravis. 
 A registry-based study. 
Author: Jintana Bunpan Andersen 
Print: AIT OSLO AS / University of Bergen
 3 
Contents 
SCIENTIFIC ENVIRONMENT................................................................................... 5 
ACKNOWLEDGEMENTS ......................................................................................... 6 
ABSTRACT ................................................................................................................. 8 
LIST OF PUBLICATIONS .......................................................................................... 9 
ABBREVIATIONS .................................................................................................... 10 
1. INTRODUCTION ............................................................................................. 12 
1.1 Brief historical outline ................................................................................ 12 
1.2 Epidemiology of MG .................................................................................. 15 
1.3 Pathophysiology, antigenic targets and autoantibodies in MG ................... 17 
1.3.1 Structure and function of the neuromuscular junction ................... 17 
1.3.2 AChR and anti-AChR autoantibodies ............................................ 18 
1.3.3. The agrin/LRP4/MuSK signaling pathway.................................... 19 
1.3.4 Thymoma-associated autoantibodies .............................................. 21 
1.4 Classification and subgroups of MG ........................................................... 22 
1.4.1 MG with AChR-antibodies............................................................. 22 
1.4.2 MG without AChR-antibodies ....................................................... 25 
1.5 Diagnosis of MG ......................................................................................... 27 
1.6 Treatment of MG ........................................................................................ 31 
1.6.1 Symptomatic treatment ................................................................... 31 
1.6.2 Long-term immunotherapies .......................................................... 32 
1.6.3 Thymectomy ................................................................................... 35 
1.6.4 Acute treatment .............................................................................. 36 
1.6.5 Supplementary treatment ................................................................ 37 
1.7 Comorbid conditions in MG ..................................................................... 39 
1.8 The course of MG ..................................................................................... 42 
 4 
1.9 Registry-based epidemiological research ................................................. 42 
2. AIMS OF STUDY ............................................................................................. 45 
3. MATERIALS AND METHODS....................................................................... 46 
3.1 Data sources .............................................................................................. 46 
3.2 Study Population ............................................................................... 48 
3.3 Statistical methods and definitions .................................................... 49 
4. RESULTS .......................................................................................................... 55 
4.1 Paper I ....................................................................................................... 55 
4.2 Paper II...................................................................................................... 55 
4.3 Paper III .................................................................................................... 56 
5. DISCUSSION .................................................................................................... 58 
5. 1 General discussion ................................................................................... 58 
5.2 Methodological considerations ................................................................. 62 
5.2.1 Study design ................................................................................... 62 
5.2.2 Internal validity............................................................................... 63 
5.2.3 Selection and information bias ....................................................... 66 
5.2.4. Confounding .................................................................................. 68 
5.2.5. External validity ............................................................................ 68 
6. CONCLUSIONS ............................................................................................... 70 
ERRATA .................................................................................................................... 71 
SOURCE OF DATA .................................................................................................. 72 
APPENDIX ................................................................................................................ 85 
ORIGINAL PUBLICATIONS ................................................................................... 88 
 
 5 
Scientific environment 
 
x The Bergen Myasthenia Gravis Research Group at the Department of Clinical 
Medicine, University of Bergen, Norway 
 
x The Muscle Study Group at the Department of Neurology, Duke University Medical 
Center, North Carolina, USA 
 6 
Acknowledgements 
This thesis was conducted at the University of Bergen, Norway, first as a medical student and 
later as a PhD-candidate in the period 2009-2015. Many persons have contributed greatly to 
this work with their knowledge and support, and to whom I would like to express my sincere 
gratitude: 
First, my principal supervisor Professor Nils Erik Gilhus who gave me the opportunity to 
start this project. His continuous encouragement and motivation have been very important to 
me. I am truly grateful for having had such an enthusiastic supervisor with a remarkable 
scientific insight and capacity. 
Professor Anders Engeland who patiently guided me through the field of epidemiological 
research and statistics. Without his help and guidance, this study would not have been 
possible. Dr. Jone Furlund Owe for his knowledge of myasthenia gravis, registry-based 
research and (much needed) moral support. 
A special thanks to Dr. Anne Taraldsen Heldal, my great friend and colleague who 
introduced me to myasthenia gravis and epidemiological research, and especially for the 
valuable comments on my thesis. The rest of the Bergen Myasthenia Gravis research group 
Dr. Jana Midelfart Hoff, Dr. Geir Olve Skeie, Dr. Fredrik Romi, Dr. Yu Hong and Dr. Aliona 
Nacu for a stimulating research environment.  
Dr. Donald B. Sanders, Mrs. Lynda Sanders, Dr. Janice M. Massey, Dr. E. Wayne Massey, 
Dr. Jeffrey T. Guptill, Dr. Vern C. Juel, Dr. Lisa Hobson-Webb, residents, fellows and staff 
at the Department of Neurology at Duke University Medical Center for the warm welcome I 
received during my visit and for generously granting me access to data from the Myasthenia 
Gravis Patient Registry and providing me with valuable clinical insight in myasthenia gravis 
patient care. 
My faithful and fabulous friends through medical school Kristin, Simone, Katinka, Kari-
Elise, Ida, Tone and Ann-Kristin for all your advice, positivity, shared frustrations and 
laughs. Your friendships have been invaluable to me! 
 7 
The administrative staff, especially Jorunn Skei, Marianne Stien and Elisabeth Bjerke for 
their assistance. 
My family Somkid, Ernst and Marita for their endless support. Bjarne: Thank you for your 
enthusiasm, love and profound interest in my work. Finally, my biggest fan, Atirat who is no 
longer with us, who I know would have been extremely proud.  
 8 
Abstract 
Background: Autoimmune myasthenia gravis (MG) is a rare neuromuscular transmission 
disorder. The pathophysiologic mechanisms are well-studied, but the etiology remains 
unknown. The clinical course of MG is still characterized by remissions and exacerbations. 
Identifying prognostic factors may be helpful when choosing treatment strategies in MG 
patients. Studies on MG epidemiology report increasing prevalence and incidence of the 
disease. However, the reported data on MG epidemiology and of prognostic factors vary 
considerably, reflecting differences in study design, case ascertainment and measurements of 
clinical severity and outcome.  
Objectives: First, we aimed to determine the prevalence, incidence and gender specific 
characteristics of MG patients needing drug treatment in a well-defined population cohort. 
Second, we examined the total drug treatment and comorbidity in MG patients. Finally, we 
aimed to assess the clinical course of MG, and to identify prognostic factors that may 
contribute to a good outcome in MG patients. 
Materials & Methods: Patient information in papers I and II was retrieved from the 
Norwegian Prescription Database, which contains information on all prescription drugs 
expedited in Norway since 2004. In paper III, comprehensive clinical information on MG 
patients treated in a consistent fashion for over three decades was obtained from the 
Myasthenia Gravis Patient Database at Duke University Medical Center (North Carolina, 
USA). 
Results & Conclusions: The point prevalence of symptomatic MG in a complete Norwegian 
cohort 1 January, 2008 was 131 per million inhabitants, and the incidence rate for the year 
2007 was16 per million. Our calculated prevalence and incidence is in agreement with other 
population-based studies. MG patients are more often treated with non-MG prescription 
drugs than patients using drugs for most other conditions, reflecting frequent comedication 
and medical comorbidity. The prognosis of MG is favorable for the majority of patients, 
regardless of age, maximum disease severity and antibody status. 
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1.  Introduction 
1.1 Brief historical outline 
The historical report from 1644 of Chief Opechankanough, a Native American Indian, 
was probably the first described case of myasthenia gravis (MG):1  
 “The excessive fatigues he encountered wrecked his constitution; 
 his flesh became macerated; his sinews lost their tone and 
 elasticity; and his eyelids were so heavy that he could not see unless 
 they were lifted up by his attendants. (…) He was unable to walk; 
 but his spirit rising above the ruins of his body directed from the 
 litter on which he was carried by his Indians.”  
Later, in 1672, the characteristic variability of weakness in the limbs and bulbar 
muscles was described in a patient by the English physician Thomas Willis.2 Willis is 
accredited the recognition of the disease as a distinct clinical entity.3  
The Greek words for muscle (myo) and weakness (asthenia) and the Latin word for 
severe or grave (gravis) have given name to myasthenia gravis.4 The gravis part of the 
word refers to the severity of the disease before any treatment was available.5 The 
name was first introduced in 1895 by Friedrich Jolly, describing two cases under the 
title myasthenia gravis pseudo-paralytica.3 Until then, the disease was known as the 
Erb-Goldflam symptom-complex, after the two physicians who first characterized the 
distinct clinical features of MG.6 
For the patients with a severe disease, the mortality was high (Figure 1). As 
mechanical ventilation was not invented until 1929 (Philip Drinker’s “the iron 
lung”),5 no remedy for patients with fatal weakness of the respiratory muscles was 
available. The effect of physostigmine, an cholinesterase inhibitor, on MG symptoms 
was first successfully applied in MG patients by Dr. Mary Walker in 1934.7 This 
discovery drastically improved the quality of life for MG patients,8 and 
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anticholinesterase drugs are still the principal drugs of choice in symptomatic 
management of MG today.  
The involvement of the thymus was already observed in the late 1800s,9 and the link 
was established in the early 1900s from several autopsy reports.10-12 In the 1930s, 
convincing evidence of improvement of myasthenic symptoms following thymectomy 
with long-lasting remission in patients both with and without thymic tumors,13;14 
established thymectomy as a therapeutic intervention in the management of MG 
patients. 
Over the next two decades, the understanding of the underlying mechanisms causing 
myasthenic symptoms was rapidly progressing. At the end of the 1950s, several 
observations of the autoimmune etiology in MG were emerging.4 Simpson was the 
first to propose this novel hypothesis that MG was an autoimmune disorder caused by 
an antibody directed at a specific protein in the neuromuscular junction (NMJ).15 
By 1973, Patrick and Lindstrom managed to demonstrate the autoimmune response to 
the acetylcholine receptor (AChR).16 They discovered that rabbits immunized with 
purified muscle-like AChR developed muscle weakness which was reversible with 
acetylcholinesterase inhibitors (edrophonium or neostigmine). This model became 
known as experimental autoimmune MG and was later widely used to study various 
aspects of the disease, including new immunotherapies.15  
With the understanding of the impairment of the neuromuscular transmission being 
caused by anti-AChR antibodies against the NMJ, immunosuppression became a 
fundament in MG therapy.4 Prednisone and azathioprine have been the mainstay in 
the management of MG since the 1970s, together with plasma exchange for acute 
exacerbations after experiments showing remarkable improvement in MG 
symptoms.17 The beneficial effect of plasma exchange was inversely correlated with 
the level of AChR antibodies, confirming that MG symptoms were caused by 
circulating antibodies.18  
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As advances in diagnosis and therapy have been evolving, the prevalence of known 
cases of MG has correspondingly increased (Figure 1). Acute exacerbations and 
myasthenic crisis with life-threatening respiratory failure are today effectively 
handled at modern intensive care facilities,19 and MG-related deaths are now under 
10%.20;21 Spontaneous remissions are still rare, but long-lasting remissions are 
observed in about 20% of the patients, usually after thymectomy.20;21 More common 
are pharmacologic remissions (PR), defined as absence of MG symptoms while on 
immunosuppressive therapy.22 From being regarded as a severe, disabling disease, 
with optimal treatment, the long-term prognosis in the majority of MG patients is 
good and the life-expectancy normal.23;24 
 
 
Figure 1. Known prevalence and mortality from MG during 1900 to 2000.  
  
From: Grob D, et al (2007): Lifetime course of myasthenia gravis.20 
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1.2 Epidemiology of MG 
Studies on MG epidemiology have been conducted worldwide over the past 60 years, 
some population-based, but mostly on hospital-based populations and case series.25;26 
Geographically, a substantial contribution of population-based studies derives from 
European countries, especially United Kingdom, Scandinavia, Italy and Holland.25 
With the advent of modern computer technology and accelerated computer capacity 
and memory, comprehensive databases are rapidly becoming a major resource in all 
fields of research. Studies using nationwide clinical and/or administrative databases to 
assess different aspects of MG, including epidemiology are increasing, most recently 
from Scandinavia, Australia and Taiwan.27-30  
MG is an uncommon neurological disorder. Reported annual incidence has gradually 
increased from 1.4-9.1 per million inhabitants in the1950s-80s31-39 until 24.9 per 
million in 2012.29 This increasing trend is particularly profound in the elderly.40;41 
Consequently, over the past six decades, MG prevalence has risen from less than 30 
per million42 to over 300 per million in 2014.43 In Norway, the prevalence has 
increased from 21 per million in 195142 to 90 per million 30 years later.34 Another 
three decades later, the prevalence of MG in Norway is around 130-145 per 
million.44;45 Factors explaining these trends are increased recognition of MG due to 
better diagnostic tools, enhanced awareness among neurologists, increased longevity 
of the population and changes in lifestyle, environmental or genetic factors. Improved 
treatment with no increased death rate in MG patients influences prevalence heavily, 
but not incidence. 
MG can develop in both men and women, at all ages and in all races. Disease onset is 
influenced by age and gender (Figure 2). MG onset after the age of 50 years used to 
be considered rare.46 Differences in age at onset between the two genders were 
noticed already in the 1900s; females were younger at onset than males,47 with three 
times more incident female than male cases before the age of 50 years. After which, 
males are more often affected than females.20;47Somnier et al demonstrated a bimodal 
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distribution for both genders in 1991 and postulated that early and late onset MG were 
two distinct disease entities.38  
There are distinct age and gender differences in disease onset between populations. 
Childhood MG with onset under the age of 15 years is more common in Chinese and 
Japanese populations, in up to 30% of the cases, most of these with purely ocular 
manifestations. Interestingly, only 10-15% childhood MG was found in the Taiwanese 
population, similar to European and North American populations.30;48 Only a few 
studies have assessed racial differences in Caucasians and African-Americans. In 
these studies a more severe form of MG in African-Americans were observed.49;50 
Figure 2. Age and sex specific incidence of symptomatic MG in Norway. 
 
From: Andersen JB, et al (2010): Myasthenia gravis requiring pyridostigmine treatment in a 
national population cohort.44 
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1.3 Pathophysiology, antigenic targets and autoantibodies in MG 
1.3.1 Structure and function of the neuromuscular junction 
The neuromuscular junction (NMJ) is made up of three main parts:4 
1. The presynaptic motor nerve terminal, responsible for synthesis, storage and  
release of the neurotransmitter acetylcholine (ACh). 
2. The synaptic cleft containing acetylcholine esterase (AChE). 
3. The postsynaptic membrane, with deep folds and densely packed with AChR at the 
top of the fold. Proteins involved in clustering of the AChR are also on the muscle 
membrane, close to the AChR, including Rapsyn, muscle-tyrosine kinase and agrin.  
 Figure 3. Muscle autoantigens in MG 
 
ACh: Acetylcholine; AChR: Acetylcholine receptor; ColQ: Collagen Q; LRP4: Lipoprotein-
related protein receptor 4; MuSK: Muscle-Specific tyrosine kinase; RyR: Ryanodine receptor. 
From: Meriggioli, MN et al (2012): Muscle autoantibodies in myasthenia gravis: beyond 
diagnosis?51 
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Neuromuscular transmission is precipitated by calcium influx to the motor nerve 
terminal through voltage-gated calcium channels (VGCCs). Acetylcholine (ACh) is 
then instantly released into the synaptic cleft, where it diffuses to reach and bind the 
AChR. This interaction triggers the opening of the AChR ion channel, resulting in 
depolarization of the muscle membrane and generation of the muscle action potential 
with subsequent muscle contraction. The ACh is rapidly destroyed by the AChE. 
Repolarization of the motor nerve terminal is induced by opening of the voltage-gated 
potassium channels (VGKCs). Several proteins on the postsynaptic membrane are 
antigenic targets in MG (Figure 3).15  
 
1.3.2 AChR and anti-AChR autoantibodies 
The nicotinic AChR at the muscle endplate is a transmembrane protein, consisting of 
five subunits forming a pentameric, fast-reacting ion channel. There are two isoforms 
of this oligomeric protein; an embryonic form made up of two identical α-subunits, 
which contain the binding site of the ACh, and three different subunits; β, ε and δ. In 
the adult form, the ε-subunit has been substituted for the γ-subunit. Other 
characteristics of the maturation of the NMJ are folding of the muscle membrane, the 
increasing number and density of the AChRs, a slower receptor turnover rate and 
decreased channel opening time.52;53 
The AChR-antibodies are polyclonal and invariably immunoglobulin G (IgG). All 
four subclasses may be found in MG patients, but most commonly are IgG1and IgG3, 
both effective complement activators. IgG2 and IgG4 are only found in very low 
concentrations and activate complement poorly (IgG2) or not at all (IgG4).54 The 
AChR-antibodies bind preferentially to the main immunogenic region of the α-
subunit.55 The pathogenicity of the AChR-antibodies is mediated through three main 
mechanisms: 
 (A) Binding and crosslinking of the AChRs, resulting in an increased 
 endocytosis and degradation of the AChRs.56 
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 (B) Binding and activation of complement factors causing destruction of the 
 muscle membrane and leading to altered membrane morphology, which 
 becomes flat instead of folded.57 
 (C) A more unusual effector mechanism is the binding of AChR-antibodies to 
 the binding site of the ACh, blocking the function of the AChR.58 
This results in reduced number of functional AChRs and neuromuscular transmission 
failure. AChR-antibodies can bind both the adult and embryonic isoforms of the 
AChR, usually with different affinity. In maternally mediated neonatal MG, high-
affinity antibodies towards the embryonic isoform cross the placenta, causing 
neuromuscular transmission failure in the fetus.59 
 
1.3.3. The agrin/LRP4/MuSK signaling pathway 
MuSK is localized at the postsynaptic membrane of the NMJ and is the main 
autoantigen identified in MG patients without AChR-antibodies (ref). Together with 
the low-density lipoprotein receptor-related protein 4 (LRP4), MuSK functions as a 
receptor for agrin.60 Agrin is a large extracellular protein which is released by the 
nerve terminal during synapse development. A tetrameric complex is formed from the 
binding of agrin to LRP4, which interacts and activates MuSK, resulting in the 
clustering of AChRs.61 Ablation of genes encoding for agrin, MuSK or LRP4 
prevents NMJ formation.62-65 
MuSK-antibodies  
Autoantibodies against MuSK was first discovered in 2001 in patients without AChR-
antibodies (termed ‘seronegative MG’).66 MuSK-antibodies and AChR-antibodies are 
never present at the same time.67 Antibodies against MuSK are mostly of the IgG4 
subclass and do not activate complement.68 The pathological mechanisms in which 
MuSK-antibodies induce MG have until recently been unclear. Several observations 
these recent years have led to the unravelling of the myasthenogenic effect of anti-
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MuSK IgG4: IgG4 levels in MuSK patients correlate with disease severity,69 and the 
IgG4 from MuSK sera alone may induce MG directly.70 In contrast, AChR-antibodies 
cause MG mainly through complement activation and accelerated internalization of 
the AChRs.4  
Studies using immunized MuSK-MG mice provided evidence of electrophysiological 
disruptions both pre- and postsynaptically.71;72 In 2012, MuSK IgG4 was proven 
directly pathogenic, without additional immune components, causing both pre- and 
postsynaptic dysfunction.73 In vitro electrophysiological and histological studies using 
muscle biopsies from MuSK-MG patients confirm these findings showing low levels 
of presynaptic ACh release, small miniature endplate potentials, partially denervated 
postsynaptic areas and degradation of postsynaptic folds.74 However, further studies 
are needed to fully understand the pathological mechanisms of IgG4 in MuSK-MG 
patients. 
LRP4-antibodies 
LRP4-antibodies in MG sera without AChR- or MuSK-antibodies were first 
identified in 2011,75 and also on rare occasions in AChR- and MuSK-positives.75-77 
The pathogenicity of LRP4-antibodies includes: Inhibition of the agrin/LRP4/MuSK 
pathway, and thereby clustering of AChRs; complement activation and lysis of the 
postsynaptic membrane as LRP4-antibodies are mainly IgG1 and IgG3 with ability to 
activate complement;78 compromised release of ACh from presynaptic vesicles.78 The 
latter could explain why such antibodies are found in patients with Lambert-Eaton 
myasthenic syndrome (LEMS),75 which is caused by autoantibodies against the 
VGCC at the presynaptic membrane.79  
Agrin-antibodies 
In 2014, two independent groups reported that antibodies against agrin were identified 
in MG patients without detectable AChR-, MuSK- or LRP4-antibodies.80;81 Some 
patients were double or even triple positive with both anti-agrin and anti-
AChR/MuSK/LRP4 in their sera, suggesting multiple antigenic targets with more 
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severe disease in these patients.70;77 The clinical significance of these findings is not 
yet clear, but as agrin is crucial in the development and maintenance of the NMJ,82 
interference with the agrin/LRP4/MuSK pathway by anti-agrin might lead to a 
reduction of functional AChRs and impairment of neuromuscular transmission.83 
 
1.3.4 Thymoma-associated autoantibodies 
Thymoma-associated autoantibodies are important as diagnostic and prognostic tools 
in MG, as their presence is correlated with disease severity and presence of thymoma. 
Titin-antibodies 
Titin is a large intracellular protein of the skeletal and cardiac sarcomere. Together 
with other muscle proteins, titin is important for muscle cell elasticity. Antibodies 
against titin, discovered in 1990 by Aarli et al,84 are found in 95% of MG patients 
with thymoma,85 and in 30-50% of late onset MG, usually in patients older than 60 
years.86;87 The presence of titin-antibodies in MG patients with a late onset correlates 
to disease severity.88 Titin-antibodies are rarely seen in MG patients with an early 
onset, and the presence of such antibodies in these patients is highly suggestive of a 
thymoma.89 
RyR-antibodies 
The RyR is a calcium channel of the sarcoplasmic reticulum. The release of calcium 
from the sarcolemma through the receptor into the cytoplasm is essential in muscle 
contraction. The RyR-antibodies were described by Mygland et al in 1992,90 but their 
pathogenic role is not yet established. Presence of RyR-antibodies serves as a marker 
of a more severe and prolonged disease, with poorer chance of a favorable outcome 
after thymectomy in MG patients with a late onset, and strongly indicates the presence 
of a thymoma.91;92 When testing for RyR- and titin-antibodies in combination, the 
sensitivity and specificity is 95%, yielding a positive predictive value for a thymoma 
in MG of 70%.85 
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VGKC KCNA4 
The VGKC is a transmembrane ion channel, mainly found in the brain, peripheral 
nerves and skeletal and heart muscles. Channel opening repolarizes the nerve terminal 
after an action potential. Antibodies to the KCNA4 (formerly Kv1.4) subfamily of 
VGKCs are seen in up to 30% of MG patients. In the Japanese population, KCNA4-
antibodies are associated with a more severe form of MG, with bulbar symptoms, 
presence of thymoma and myasthenic crisis.93 This was not the case in Caucasians, 
who had mild clinical presentation.94 The clinical role of these antibodies therefore 
needs further clarification. The KCNA4-antibodies are useful as markers of the 
potential development of severe autoimmune myocarditis and response to calcineurin 
inhibitors.95 
 
1.4 Classification and subgroups of MG 
The heterogeneity of MG is reflected by the antibody diversity, clinical expression, 
thymic pathology, age at onset and associations to human lymphocyte antigen (HLA). 
The different subgroups have distinct clinical features with implications for treatment. 
There is no consensus regarding classification of MG subgroups. In this thesis, we 
classify MG by the presence or absence of AChR-antibodies. 
 
1.4.1 MG with AChR-antibodies  
AChR-antibody positive MG (AChR-MG) 
85-90% of MG patients have detectable antibodies against the nicotinic AChR-
antibodies, representing the largest MG subgroup.96;97 Four distinct subtypes of 
AChR-MG are recognized: 
1. Early onset MG (EOMG)  
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This is the classic form of MG, most often seen in younger women with a female to 
male ratio being three to one. An early onset of MG used to be defined as onset of 
MG symptoms before the age of 40 years. This age cut-off was first introduced by 
Compston et al as an arbitrary age limit to study non-thymoma patients.98 They found 
a gender bias in disease presentation according to age; females were younger at 
disease onset than males. Later studies on the age and gender specific incidence of 
MG suggested 50 years of age as a cut-off to better reflect pathogenetic differences in 
disease onset.38;47;99 The EOMG subgroup used to constitute 60% of AChR-MG. Over 
the past decade, however, the rate of patients with onset after 50 years has increased, 
while the rate of patients with onset before 50 years has been stable or even 
decreasing.40;100;101 
In addition to AChR-antibodies, titin-antibodies may be detected in about 10% of 
EOMG patients, while RyR-antibodies are rarely present.85 The thymus in EOMG is 
usually hyperplastic with germinal centers, which are sites of B-cell response against 
the AChR.102 There is a strong association with the HLA-DR3, and B8 alleles in this 
subgroup.98;103 Other autoantibodies or autoimmune diseases, such as autoimmune 
thyroid disease and systemic lupus erythematosus (SLE), occur more often in these 
patients than in patients with a later disease onset.104;105 
2. Late onset MG (LOMG)  
LOMG is defined as onset of MG symptoms after the age of 50 years, the female to 
male ratio being near equal. 46;106 With emerging epidemiologic evidence of 
increasing incidence of the very old MG patients, the age cut-off of 60 and 70 years 
has been proposed for LOMG.106;107 This subgroup now constitutes over 50% of 
AChR-MG.107 
In most patients thymus is atrophic, that is normal for age, and thymus hyperplasia is 
unusual.107 In addition to AChR-antibodies, 60% have titin-antibodies, and 15% RyR-
antibodies.85 The presence of titin-antibodies seem to correlate with a more severe 
disease.88 LOMG seldom has other autoimmune diseases.108 There is an association 
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with HLA-B7, -DR2, -DR7 and -DRB1*15:01 in this patient group,98;103 HLA-DR7 is 
particularly found in LOMG patients with anti-titin antibodies.109 LOMG may present 
with ocular or generalized weakness, with lower disease activity than EOMG and a 
favourable prognosis.46 However, complete stable remissions (CSRs) are rare, and 
mortality is higher compared to EOMG, most likely attributable to age and comorbid 
conditions.106 
3. Ocular MG 
Patients with purely ocular manifestations constitute about 10-20% of AChR-MG 
patients, and may present at any age and in both genders.110 When the symptoms 
manifest themselves to other parts of the body, the disease is termed ‘generalized’. 
Ocular MG is localized to the extra-ocular muscles. Ptosis and diplopia are the first 
signs of the disease in up to 85% of MG patients. If the disease has not generalized 
within the first two years after symptom onset, which is the case in about 80% of the 
patients, it is likely to stay purely ocular.111 There is an ongoing debate whether or not 
early corticosteroid treatment limits the conversion from ocular to generalized 
disease.  
Half the patients with ocular MG have detectable antibodies against the AChR in 
routine assays, whereas additional patients have AChR-antibodies detected when 
using a cell-based assay.112 MuSK-antibodies are rarely found in ocular MG, and 
thymic histology is largely unknown.51;110 Reported rate of spontaneous remission is 
about 15-18%, but the clinical course varies. 113 
4. Thymoma-MG  
Thymomas are seen in 10-15% of MG patients, and MG is the most common 
thymoma-associated autoimmune disease; 30-50% of patients with thymoma have 
MG.114 Thymomas are neoplasms derived from thymic epithelial cells. These cells are 
mixed with non-neoplastic T-cells. Thymoma-MG occurs in both males and females 
at all ages, but is typically diagnosed at 40-60 years, and rarely during the two first 
decades of life.115 Clinically, the disease tends to be more severe compared to EOMG 
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with more frequent weakness of the oropharyngeal muscles. The long-term prognosis 
regarding muscle weakness is similar to LOMG without thymoma.116 
Thymoma-MG patients have an array of antibodies. Virtually all of them have AChR-
antibodies, such antibodies also occurring in 25% of patients with a thymoma but 
with no clinical symptoms of MG. 95% have titin-antibodies and over half have RyR-
antibodies, but not antibodies against MuSK.102 Antibodies associated with 
paraneoplatic syndromes, such as anti-VGKC and -VGCC may be present.48 
Thymoma-MG patients do not have a specific HLA profile, and are seldom DR3 
positive.47  
AChR-MG with low-affinity AChR-antibodies  
Some AChR-antibodies can bind divalently to adjacent AChRs only when they are 
expressed in dense clusters. Such antibodies are not detectable by the commercially 
available radioimmunoprecipitation assays (RIAs), but can be found when using a 
cell-based assay and indirect immunofluorescence.117 About 60% of MG patients 
without AChR- or MuSK-antibodies detected in routine assays have such low-affinity 
AChR-antibodies.117 The pathogenicity of these antibodies is likely to be the same as 
for regular AChR-antibodies.118 Clinically, these patients are indistinguishable from 
AChR-MG patients, with similar prognosis and response to treatment. 
  
1.4.2 MG without AChR-antibodies 
MuSK-positive MG (MuSK-MG) 
MuSK-antibodies are reported in 5-60% of MG patients without AChR-antibodies, 
and MuSK-MG is the largest subgroup of MG patients seronegative for AChR-
antibodies, representing 5-8% of all MG cases.119 Differences in clinical 
manifestations, immune parameters, and therapeutic responses clearly establish 
MuSK-MG and AChR-MG as two distinct disease entities. MuSK-MG can occur in 
all ages, but the onset tends to be earlier, and there is a female predominance.120 The 
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occurrence of MuSK-MG seems to differ worldwide, with latitudinal correlations. 
The highest frequency of MuSK-MG is found in the Mediterranean countries and at 
similar latitudes in North America and Asia, and decreasing further north.121 Only 
five cases have been reported in Norway with a population of five millions.122 The 
rate of MuSK-MG is higher in African-Americans than in whites.50 
Most MuSK-MG patients have a generalized disease, often with a more severe 
symptomatology with bulbar, facial, neck and respiratory weakness.120 Antibody titer 
and disease severity is highly correlated in this MG subgroup.123;124 The role of the 
thymus in MuSK-MG is not fully understood. Thymomas do not have an increased 
frequency, and thymus histology is usually normal.102 There are rarely other 
autoantibodies present in MuSK-MG patients, and they seldom have additional 
autoimmune diseases.67;125 There is a strong association with HLA-DR14 and -
DQ5.126;127 The long-term prognosis is usually less favorable than in AChR-MG, with 
a lower rate of remission and a higher rate of refractory disease.119 
LRP4-MG 
The rate of LRP4-MG varies between 7% and 32% in MG patients without AChR-
antibodies.77 This subgroup may occur in all ages, and there is a female 
preponderance. Clinical presentation ranges from purely ocular manifestations to 
myasthenic crisis.75;76 In some patients, these autoantibodies were found together with 
antibodies against the AChR or MuSK. Patients with a combination of antibodies 
presented with more severe symptoms. Thymic changes identified so far include 
hyperplasia only.77 
MG without known autoantibodies (‘Triple negative MG’) 
This subgroup consists of patients lacking antibodies against the AChR, MuSK and 
LRP4. Clinical presentation is heterogeneous, representing the entire spectrum of 
disease severity. As new pathological autoantibodies are discovered (anti-agrin, -
Collagen Q and -rapsyn), and more sensitive antibody assays are becoming available 
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(low-affinity antibody testing for AChR, MuSK and others), the true prevalence of 
this MG subgroup is probably very low.128  
1.5 Diagnosis of MG 
The diagnosis of MG is based on typical MG symptoms and signs, response to 
pharmacological tests, positivity of antibody assay testing, electrophysiological 
examinations and radiological imaging. 
Clinical manifestations 
Fluctuating fatigable weakness of specific muscle groups, improving with rest and 
worsening with activity, is the clinical hallmark of MG.48 In 85% of the cases, 
weakness of the extra-ocular muscles causing ptosis and diplopia is the first signs and 
symptoms of MG.20 Generalization usually occurs within the first two years in the 
majority of patients, most commonly affecting the facial, limbs and axial muscles. In 
15%, the initial symptoms are bulbar weakness with chewing, swallowing and 
speaking difficulties. On rare occasions, the respiratory muscles are affected, 
requiring immediate medical attention. Pathological fatigue not subsiding with rest is 
another clinical characteristic of MG.129 This phenomenon is described in other 
autoimmune diseases such as multiple sclerosis and rheumatoid arthritis as well.130;131 
There is a wide range of differential diagnosis, such as motor neuron disease, multiple 
sclerosis, muscular dystrophy, polymyositis, mitochondrial myopathies, general 
fatigue, psychiatric conditions and hyperthyroidism.132 Ocular myopathies or 
neuropathies such as neuromyelitis optica should be considered in patients with 
purely ocular symptoms.133 Also, excluding other neuromuscular diseases including 
LEMS and congenital myasthenic syndromes is important. MG may easily be 
overlooked or misdiagnosed, especially in elderly patients. Ageing may cause sagging 
of the lower eyelids and make ptosis difficult to identify. Diplopia might not be 
detected due to vision impairment from macular degeneration or cataract formation, 
and dysarthria and dysphagia in elderly persons may be caused by several other 
conditions, such as cerebrovascular diseases.46 Elderly patients with MG symptoms 
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are in general practice often misdiagnosed as having a brain stem lesion, usually 
stroke. 
The patient history is essential in MG diagnostics, particularly the identification of 
any day-time variability in muscle weakness. Clinical assessments should include: 
Ocular muscles by testing the ability to maintain an upward or lateral fixed gaze for 
about 30 seconds (‘ptosis test’); facial muscles, especially eye closure; bulbar features 
such as speech and swallowing; axial muscles, i.e. neck extension and flexion; 
proximal limbs, e.g. by asking the patient to keep an arm stretched for one minute. 
Weight loss could be a sign of bulbar affection. Tachypnea or orthopnea may be signs 
of respiratory involvement and the risk of developing a myasthenic crisis is increased. 
Pharmacology 
After a diagnosis of MG is suspected following a careful clinical examination, the 
response of the suspected muscles to AChE-inhibiting drugs may be tested. Oral 
administration of pyridostigmine can be used. AChE-I available, edrophonium, 
(‘Tensilon test’) which has a rapid onset and short half-life, is preferred. The drug is 
administrated intravenously, and a marked objective improvement is considered a 
positive response, and highly specific of MG.134 This test is now used only in the 
assessment of suspected MG cases without detectable antibodies.  
Antibody testing 
The link between neuromuscular impairment and circulating AChR-antibodies was 
firmly established in 1973 by Patrick and Lindstrom.16 Three years later, Lindstrom et 
al developed an assay using radioimmunoprecipitation (RIA) to measure AChR-
antibodies in MG sera.96 AChRs prepared from humans were labelled with 125I-α-
bungarotoxin, a snake venom that binds specifically and practically irreversibly to the 
receptors. The concentration of AChRs was quantified by measuring bound toxin to 
the receptors. Next, the receptor-toxin complex was precipitated with serum from a 
suspected MG case. Different preparations of the AChR could vary in the capacity to 
bind both the toxin and the antibody. Today’s commercial kit using a radio-receptor 
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assay (RIA technique) with AChR as an antigen has high sensitivity and better 
reproducibility. The concentration of AChR-antibodies is measured in nmol/L, and a 
raised value above the cut-off (0.5nmol/L) is considered nearly 100% specific for 
MG.97 
The AChR-antibodies are detectable in only about 85% of the MG patients with 
generalized disease and about 50% of patients with purely ocular weakness. More 
sensitive cell-based antibody assays are being developed, but are not yet commercially 
available. This technique enables detection of antibodies that only bind to AChRs in 
clusters, i.e. low-affinity AChR-antibodies.117  
In patients with MG clinic, but without a positive AChR-antibody assay, MuSK-
antibodies should be assessed. As of yet, no commercial tests are available for the 
identification of LRP4-antibodies. Testing for other autoantibodies such as anti-titin 
may be important, as their presence indicates a more severe disease. Although the 
presence of AChR-antibodies is specific for MG, they may on rare occasions be found 
in patients with other autoimmune diseases, graft-versus-host disease in allogeneic 
bone marrow transplantation, thymoma without MG and neuromyelitis optica.  
Electrophysiology 
Repetitive nerve stimulation (RNS) and single-fiber electromyography (SFEMG) are 
the two most important electrophysiological tests in MG diagnostics. The decreased 
number of AChRs and the reduction of sodium channels due to altered post-synaptic 
membrane morphology result in electrophysiological abnormalities. Both factors 
contribute to a reduction in the endplate potential (EPP), which normally is larger 
than the threshold needed to generate an action potential. This difference between the 
EPP and the threshold potential is called the safety factor in neuromuscular 
transmission, and is reduced in MG.4 The release of ACh is reduced after repetitive 
activity, and the EPP may fail to reach the necessary threshold to trigger the action 
potential. The resulting decrement in amplitude of the compound muscle action 
potential seen after RNS is called the decremental response. The decrease in ACh 
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release reaches maximum after delivery of the first four stimulations of a high-
frequency train of stimuli (2-5 Hz). A decremental response >10% is considered 
abnormal. An abnormal result of the RNS is highly specific for MG with 95% 
specificity, depending on the operator and the muscles tested. The sensitivity is about 
75% in generalized MG and <50% in ocular MG.48 
The time it takes for the EPP to reach the threshold for muscle action potential varies. 
This variability may be measured as neuromuscular jitters by SFEMG. In SFMG, a 
specially designed concentric needle electrode is used to record two muscle fibers’ 
action potentials generated by a single motor neuron at the same time. Neuromuscular 
jitters occur due to the difference in time between the firing of the two muscle fibers. 
In MG, the jitter is increased in about 95-99% if the appropriate muscles are tested, 
with a high negative predictive value.135 The specificity is lower than for repetitive 
testing. Neurophysiological tests are crucial to diagnose antibody-negative MG, but 
unnecessary when AChR- or MuSK-antibodies have been detected. 
Imaging 
Thymus pathology is common in MG, and all patients with confirmed or suspected 
MG should undergo a chest CT or MRI to exclude the presence of a thymoma. 
Thymic hyperplasia and thymoma may be indistinguishable on imaging, but thymoma 
is seen as a homogeneous lobulated mass in the anterior mediastinum. A normal-sized 
thymus gland does not exclude hyperplasia, which is often impossible to diagnose by 
imaging. Contrast-enhanced CT-scan is the modality of choice for evaluation of 
thymomas,136 with high sensitivity (89%). The specificity is, however, only 77%.137  
MRI can give additional information if suspicion of tumor infiltration or invasion of 
adjacent organs or metastasis. 
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1.6 Treatment of MG 
The basis of MG management is symptomatic treatment in combination with 
immunotherapies (Figure 4). The treatment is life-long for most patients. The goal of 
treatment is to induce and maintain remission while minimizing the side-effects and 
risk of exacerbations. 
 
1.6.1 Symptomatic treatment 
The first line of treatment in MG is oral acetylcholine esterase - inhibitors (AChE-I), 
most commonly pyridostigmine bromide (Mestinon ©), but also neostigmine and 
ambenonium are in lesser degree used.138 The drug blocks the function of the enzyme 
AChE, thereby enhancing the time and amount of the neurotransmitter ACh in the 
synaptic cleft. This treatment is only symptomatic and does not affect the course of 
the disease. In some patients, usually in those with a mild disease, oral AChE-I is 
sufficient to control the symptoms.  
AChE-Is are usually well-tolerated when given in standard doses up to 60 mg five 
times a day. Increased cholinergic stimulation may cause side-effects, mostly 
muscarinic symptoms, typically stomach cramp, diarrhea and increased sweating,139 
but also nicotinic symptoms, such as muscle fasciculations and cramps.140 The side-
effects are dose-dependent, and the optimal dosage should be adjusted accordingly to 
maximize the therapeutic benefit and minimize the side-effects. Hypersalivation, 
bradycardia, excessive sweating and miosis are muscarinic symptoms of cholinergic 
overdose.139 
Patients with MuSK-MG usually respond poorly to AChE-I, or even experience 
worsening of MG symptoms. In some MuSK-mouse models, there is evidence of 
AChE deficiency, possibly explaining the hypersensitivity to AChE-I seen in MuSK-
MG patients.141 Further studies are needed to confirm this hypothesis.  
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1.6.2 Long-term immunotherapies 
Corticosteroids are the first immunosuppressive drugs of choice when symptomatic 
therapy is insufficient. Prednisolone is the preferred steroid in most European centers, 
while prednisone is the standard steroid used in the USA. The drug is taken orally, 
and the start-dose should be high enough to induce remission (up to 60-80 mg 
alternate days, or 30-60 mg daily), after which the dose is slowly tapered to the 
minimum dose required to maintain remission. A temporary worsening may be seen at 
high doses of prednisolone (‘steroid dip’), and a close observation of the patient is 
urged.138 This is the reason why some centers prefer to increase the prednisolone 
slowly in MG. 
The anti-inflammatory effects of corticosteroids are complex and not fully 
understood. These include induced apoptosis of T-cells and blocked transcription of 
inflammatory cytokines.142 Although efficient, there are serious side-effects 
associated with both short- and long-term use of corticosteroids; osteoporosis, 
diabetes, hypertension, weight gain, fluid retention, insomnia, cataract, peptic ulcer 
disease and increased risk of infections.138;142 
Azathioprine is the first drug of choice whenever long-term immunosuppression is 
required in MG.138 The drug is recommended used in combination with 
corticosteroids as a steroid-sparing agent. The combination is also more effective than 
corticosteroids alone.143 There is a delayed onset of action, and maximum effect is 
usually achieved first after 6-24 months. Azathioprine and corticosteroids are 
therefore often initially given as combination therapy for a more rapid therapeutic 
effect, after which corticosteroids are slowly reduced unless relapse occurs.  
Azathioprine inhibits DNA- and RNA-synthesis, and thereby T- and B-cell 
proliferation. The drug is well-tolerated. Flu-like symptoms and gastrointestinal 
disturbances develop in about 10%. The potential development of leukopenia and 
hepatoxicity requires careful monitoring of the blood count and liver enzymes during 
the first few months. Discontinuation of the drug usually reverses these effects.138  
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Mycophenolate mofetil (MMF) is a second-line immunosuppressant, usually reserved 
for MG patients who do not tolerate or respond to azathioprine.138 MMF inhibits 
purine synthesis specifically in lymphocytes, and has documented effects in 
inflammatory conditions such as psoriasis and SLE.144 In MG, retrospective studies 
suggest a therapeutic and steroid-sparing effect of MMF, but these effects have not 
been confirmed by randomized controlled trials.145;146 In these two trials, the patients 
were followed for 6 months only, which may have been too short considering the 
biologic effect of MMF. In the largest of the retrospective studies with follow-up time 
of 2-3 years, the beneficial effect of MMF was demonstrated, both as monotherapy 
and in combination with corticosteroids.147 These effects were evident after 6 months 
in both groups. The side-effects are usually mild, most commonly diarrhea, nausea, 
headache and infections, but there is a possible increased risk for lymphoma.148 
Ciclosporin has a well-documented steroid-sparing and therapeutic effect in MG.149 
The drug inhibits calcineurin signaling and thereby T-cell functions. Ciclosporin is a 
second-line immunosuppressant in MG due to side-effects of nephrotoxicity and 
hypertension, and is only considered when azathioprine cannot be used, or the effect 
of azathioprine is inadequate.138  
Methotrexate is proven safe and beneficial in other autoimmune diseases, but is 
poorly documented in MG. The drug is a structural analogue of folic acid and inhibits 
its metabolism, thereby inhibiting DNA synthesis. Due to the lack of beneficial effect 
in MG, methotrexate is only recommended when first-choice immunosuppressants 
cannot be used or are inadequate.138 
Cyclophosphamide has a well-documented effect on MG. The drug interferes with 
DNA replication by adding an alkyl group to the guanine base of DNA, affecting both 
B- and T-cells at high doses. Poor side-effect profile including febrile neutropenia, 
bone-marrow suppression, bladder toxicity, opportunistic infections, and carcinogenic 
and teratogenic effects, limits the use of cyclophosphamide. The drug is therefore 
only considered in patients who are intolerant or unresponsive to several other 
immunosuppressants.138 
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Tacrolimus (FK506) is proven efficient in MG at a low dose in one open trial and 
several case reports,150;151 with an additional effect in anti-RyR antibody positive 
patients.152 The drug binds to the FK506-binding protein and inhibits the T-cells 
through the calcineurin-mediated pathway. Tacrolimus also enhances the release of 
RyR-related sarcoplasmic calcium. Side-effects are dose-dependent and include 
paraesthesias, tremor, hypertension, hyperglycemia, renal insufficiency and possible 
risk of malignancy.148 The drug is recommended in patients with a poorly controlled 
disease, particularly in patients with anti-RyR antibodies.138 
Rituximab is reported efficient in MG in several uncontrolled studies, both in AChR-
MG and, particularly, in MuSK-MG.153-156 Rituximab is a monoclonal antibody 
targeted against the CD20 antigen expressed in pre-B-cells, and subsequently depletes 
B-cells. Interestingly, only the short-lived plasma cells are affected. These cells 
produce IgG4, and may explain the efficacy of rituximab in MuSK-MG, although the 
mechanism of action in MG is not fully clear.156 Rituximab may also influence T-cell 
responses. The drug is well-tolerated, and is approved in treatment of B-cell 
lymphoma and rheumatoid arthritis. Side-effects are related to the intravenous 
administration of the drug, but cases of infections, prolonged B-cell depletion, heart 
failure and progressive multifocal leukoencephalopathy have been reported.148;156 The 
patients should therefore be carefully monitored. Rituximab is often recommended for 
severe and moderate to severe MG where first line immunosuppressive therapy has 
failed.  
Eculizumab has demonstrated promising results in severe and refractory MG in one 
randomized controlled trial.157 Eculizumab is a recombinant humanised monoclonal 
antibody that binds to C5, preventing C5 cleavage, blocking the formation of a 
complement complex. Unlike other immunosuppressive therapies available in MG, 
this drug targets at the innate immune system. With the proven efficacy and safety 
from this multicenter-trial, eculizumab represents a new therapeutic approach in MG 
patients with severe and refractory disease.157 
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Etanercept, belimumab, granalocyte-macrophage colony-stimulating factor, are some 
of the emerging immunotherapy options in MG. These drugs represent more specific 
therapy, targeted at different elements of the immune system. Target-specific drugs 
are currently approved for other autoimmune disorders, but these are not yet well-
documented in MG.158 Future immunotherapeutics should aim at specific targets 
related to MG pathogenesis. 
 
1.6.3 Thymectomy 
Since Sauerbruch’s first successful thymectomy in 1911,3 several observational 
studies and controlled studies have documented the beneficial effect of thymectomy 
in MG patients without thymomas.159;160 The procedure is therefore recommended in 
MG, but not without controversy as there are no prospective studies or randomized 
controlled trials of the effect of thymectomy in non-thymoma MG. In reviewing 
studies showing positive associations between thymectomy and MG remission, 
Gronseth and Barohn demonstrated confounding differences of prognostic importance 
in the baseline characteristics between thymectomy and non-thymectomy patients. 160 
Thus, there is still a need for prospective studies to conclusively establish the benefit 
of thymectomy in non-thymoma MG.  
The chance of remission is enhanced when thymectomy is performed early rather than 
later in the course of the disease, and an early intervention is preferred.138 The 
procedure is performed either transsternally or by a video-assisted thoracoscopic 
technique (VATS). Both techniques appear equally effective, but there is better 
cosmetic result and less need of postoperative medication after VATS.161 The effect 
of thymectomy usually occurs within two years, after which immunosuppressive 
drugs often given prior to thymectomy can be tapered off.138  
EOMG patients often have an enlarged thymus, and long-lasting remission is 
observed in up to 30% after thymectomy.159 Early thymectomy is usually 
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recommended in all patients with anti-AChR-positive, early onset, generalized 
disease, with or without thymic hyperplasia.138;160  
In LOMG patients with an atrophic thymus, thymectomy is not recommended.162 
However, patients with a debut before the age of 60 years and those with thymic 
hyperplasia should be considered for thymectomy.162 The presence of titin-, or RyR-
antibodies suggests that thymectomy may be less beneficial. 
In ocular MG, there is no evidence of better clinical outcome after thymectomy, and 
thymectomy is therefore not recommended in this group.113 There are some 
conflicting results of thymectomy in MuSK-MG, but thymectomy is not 
recommended in this group based on the evidence available.138 In AChR- and MuSK-
antibody negative patients with an early onset, thymectomy is recommended if 
presence of low-affinity AChR-antibodies is detected or suspected.138 
Thymoma is an absolute indication for thymectomy. Patients with thymoma often 
show no clinical improvement after thymectomy, although younger patients may have 
some benefit. The goal of thymectomy in these patients is therefore to treat the 
cancer.138 
 
1.6.4 Acute treatment  
Plasma exchange (PE) and intravenous immunoglobulin (IVIG) represent two 
immunosuppressive therapies with a rapid onset of action and are used when acute 
intervention is required, e.g. exacerbations or myasthenic crisis, and also to prepare 
for thymectomy. Both are proven effective and safe in MG.163 During PE, 
autoantibodies are removed from sera by membrane filtration or centrifugation. PE is 
used also in patients without detectable autoantibodies. IVIG is a concentrated 
solution of immunoglobulins, mostly IgG. The mode of action is complex and 
includes cytokine inhibition, neutralization of activated complement and 
autoantibodies.164 Both PE and IVIG are short-term treatments. The therapeutic effect 
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occurs within 2-5 days and lasts for about 4-12 weeks. Both randomized and non-
randomized evidence show equal efficacy for both treatment modalities in MG 
exacerbations.165;166 IVIG has a better side-effect profile and is easier to administer 
than PE, and is thus the preferred option in many centers.138;166 The two treatments 
can be given sequentially. 
Myasthenic crisis 
Myasthenic crisis is defined as severe weakness that requires intubation or delayed 
extubation following surgery.5 Up to 20% of MG patients experience a myasthenic 
crisis over the course of the disease.19 Risk factors include surgery and drugs that may 
worsen MG symptoms, but in 70% of the cases, the crisis is precipitated by an 
infection.167 In many cases, the cause is unknown.  MG may start with severe 
respiratory failure, and in MG patients with a confirmed disease, deterioration to 
myasthenic crisis is easily recognizable.  
Prompt recognition and intervention with respiratory support is life-saving. AChE-Is 
increase bronchial secretion, temporary discontinuation is therefore often 
recommended.168 PE or IVIG should be given. Available evidence may indicate a 
slightly better effect of PE over IVIG in myasthenic crisis.163 The chosen modality 
should be combined with high dose steroids during the recovery. Long-term 
immunosuppressive treatment is recommended to maintain the effect of PE or 
IVIG.169 AChE-Is should be reintroduced early.169 The mortality of myasthenic crisis 
is less than 5%.19 
 
1.6.5 Supplementary treatment 
A serious complication of long-term steroid treatment is osteoporosis, and 
bisphosphonate and supplements with calcium and vitamin D should be considered in 
all patients.142 A sedentary lifestyle due to fatigue and muscle weakness combined 
with weight gain and increased glucose tolerance as results of steroid treatment 
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contribute to an increased risk of cardiovascular diseases. Lifestyle modifications 
such as weight reduction may be important, although the scientific basis is lacking.138 
Physical training improves muscle strength and is safely recommended in mild and 
moderate MG.138 Respiratory muscle training may strengthen the respiratory muscles 
and improve lung function.170 Infections should be treated aggressively, and seasonal 
flu vaccination should be recommended in MG patients.138 
 
Figure 4. Treatment flowchart.  
 
 
 
From: Meriggioli MN, et al (2009): Autoimmune myasthenia gravis: emerging clinical and 
biological heterogeneity.48 
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1.7 Comorbid conditions in MG 
Muscle weakness in MG is in most patients effectively treated, but the management 
of MG may be complicated by comorbid conditions, consequently affecting the 
quality of life and outcome. Comorbidity are linked to MG subgroups.125 
Autoimmune comorbidity 
The risk of a second autoimmune disorder is increased in MG patients compared to 
non-MG, with a frequency of 15%, most frequently in EOMG, but with a higher 
frequency also in LOMG compared to the non-MG population.171 In a systematic 
review, autoimmune thyroid disease, SLE, diabetes mellitus and rheumatic arthritis 
were identified as the most frequent autoimmune disorders associated with MG.172 
More recently, a population-based study from Sweden found the strongest association 
between MG and polymyositis/dermatomyositis, SLE and Addison’s disease, 
especially for EOMG. All these disorders are associated with the HLA-B8-DR3 
haplotype.173 This shared haplotype is confirmed in genome-wide association studies 
in EOMG.174 
Cardiac disease 
Cardiac involvement in MG is recognized, especially in association with thymoma 
through growth and local invasion.171;175 MG-specific cardiac muscle antibodies were 
shown by Mygland et al in 1991.176 Reactive cardiac autoantibodies have been 
described in thymoma-MG and LOMG. About half of all MG patients and nearly 97% 
of all thymoma-MG patients have antibodies against titin and RyR, targeting both 
striated and cardiac muscle in vitro. More recently, antibodies against the β- 
adrenergic receptors, muscarinic AChRs and VGKC (KCNA4) have been reported. 
The latter has been suggested as a possible marker for cardiac involvement in MG, 
especially myocarditis, which occurs more frequently in MG compared to other 
autoimmune disorders, particularly in thymoma-MG.95;171 Minor cardiac dysfunctions 
have been shown in functional imaging studies177;178 and electrocardiographic 
findings such as T-wave abnormalities and QT-prolongation have been reported.175 
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The clinical significance of these findings is not yet determined. Deaths from cardiac 
diseases are not increased in MG patients.23  
Respiratory tract disease and infections 
The vital capacity is reduced in 39% of MG patients, and the risk of severe respiratory 
tract disease is increased in MG.20;23 Modern day intensive care facilities have aided 
the decline of deaths due to respiratory disease in MG to near normal.23 Infections 
may precipitate MG worsening, and should be treated aggressively, especially of the 
respiratory tract, as respiratory muscle weakness can lead to myasthenic crisis.171 
Cancer 
Studies regarding cancer risk in MG are limited and conflicting. Most existing case-
control studies have methodological limitations, and MG subgroups are rarely 
assessed.171 In two large Taiwanese population-based studies, the risk of cancer in 
non-thymoma MG was overall increased, specifically for lymphoma.179;180 This 
overall increased cancer risk was not confirmed by Pedersen et al in a national case-
control study, combining several nationwide registries.181 The Danish authors did, 
however, find a slight increase in the risk of overall cancer in patients with long-term 
use of azathioprine. In patients with both long-term use and high cumulative doses of 
azathioprine, the risk of lymphomas was also increased.182 Unfortunately, the type of 
lymphoma could not be evaluated. Also, the risk estimates were based on small 
numbers. Long term use and high doses of azathioprine was also associated with 
highly increased risk of non-melanoma skin cancer.183 Among Norwegian MG 
patients, cancer was not overrepresented as a cause of death.23 The 
lymphoepithelioma in thymoma-MG increases the risk of cancer, and is not related to 
autoimmunity.184 
Drugs 
Several drugs may cause worsening of MG symptoms, or even unmask latent MG or 
cause transient myasthenic symptoms, due to increased neuromuscular blocking.185 
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Such drugs include several antibiotics, cardiovascular drugs, analgesics, 
anticonvulsants, psychotropics, anti-rheumatics, antimalarials, eyedrops and 
endocrine thyroid replacement therapy.186 The initiation and maintenance of such 
drug therapy in MG should therefore be carefully monitored, and the patients 
informed of potential worsening of symptoms. D-penicillamine is contraindicated in 
MG.187 Cases of D-penicillamine-induced MG have been reported. Discontinuation 
reverses the MG symptoms.188  
Pregnancy and delivery 
Complications during pregnancy and surgical interventions during delivery in MG 
women occur slightly more frequently compared to non-MG women.189 Spontaneous 
abortion is not increased, and vaginal delivery is safe in most cases. During 
pregnancy, the women should be followed by a team of obstetricians, neurologists and 
pediatricians. The course of MG during pregnancy is variable. About 30% experience 
MG worsening, usually during the first trimester. Puerperal infections may increase 
the risk of MG exacerbation, requiring prompt treatment. In 20-40%, symptom 
improvement is observed during the second and third trimester, probably due to the 
reinstated immunosuppression.190 The clinical course varies between different 
pregnancies. The long-term outcome of MG is not worsened by pregnancy, and 
conception is not discouraged.190  
Transient neonatal MG occurs in 10-20% of infants of MG mothers, due to placental 
transmission of IgG antibodies. The antibodies are cleared naturally postpartum. 
Symptoms of weak sucking and crying, dysphagia, hypotonia and respiratory distress 
are in these babies evident within the first two days after delivery and can persist 
during the first four weeks of life, often only for days, however. Maternal MG can in 
rare cases cause arthrogryposis multiplex congenita, which is defined as non-
progressive congenital contractures and malformations, due to lack of fetal movement 
in utero. Maternal MG severity is not correlated with occurrence of neonatal MG or 
arthrogryposis multiplex congenita. Breastfeeding is normally encouraged, but should 
be avoided in newborns with severe neonatal MG.190 
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1.8 The course of MG 
Despite advances in therapy, the course of MG remains variable. Spontaneous 
remissions are rare. The long-term outcome is generally good, with a life-expectancy 
near normal. Deaths due to MG exacerbations or crisis are very rare. Nevertheless, 
long-lasting remissions are only obtained in about 20% of the patients, usually after 
thymectomy. Prognostic factors include age at onset and time of diagnosis from 
onset.191  
The clinical course of MG seems to be determined within the first two to three years 
after disease onset, with maximum disease severity occurring within this time period. 
70% reach the maximum level of severity during the first year of onset, and 85% 
during the first three years.111 In subsequent years, the patients usually improve or 
attain a more stable disease. 
In about 85% of all patients, the disease becomes generalized. 66% of the patients 
with only ocular manifestations at disease onset were found to develop a generalized 
disease.111 If generalizations have not occurred within the first two years in patients 
with a debut of ocular MG, the disease is most likely to remain purely ocular. 
 
1.9 Registry-based epidemiological research  
Epidemiology is defined as “the study of the distribution of disease and determinants 
of health-related states or events in specified human populations, and also the 
application of such studies to the control of human health problems.”192 The aims of 
epidemiology are to elucidate disease etiology and to determine the risk factors for the 
disease, and thereby ultimately to develop strategies for prevention of the disease. In 
clinical settings, epidemiology seeks to “make predictions about individual patients 
by counting clinical events in similar patients, using strong scientific methods for 
studies of groups of patients to ensure that predictions are accurate”.193 
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National health registries represent a new opportunity of studying health problems on 
complete populations, with enhanced power, less bias, and are less time- and cost-
consuming for the individual researcher. On the other hand, detailed clinical 
information is often missing. Linkage of different central health registries may to 
some degree overcome this issue. Most central health registries are based on ‘silent 
consent,’ i.e. any individual whom do not wish to have their health information stored 
in central health registries have to actively reserve themselves. This may represent an 
ethical challenge for researchers and the providers of the registries. Access to data is 
therefore subject to an extensive, and often times lengthy, application process. 
Clinical patient registries usually contain more detailed information about individual 
patients, and are based on written, informed consent, but are usually prone to 
selection bias. The strengths and limitations of registry-based populations are 
discussed in depth in chapter 5.2 ‘Methodological considerations’. 
Ethical considerations 
The Norwegian Institute of Public Health (NIPH) is the provider of several of the 
central health registries in Norway. NIPH collects, stores and maintains the registries, 
with the goal of facilitating research and health surveillance of the population. Health 
information stored in the central health registries in Norway is regulated by the 
Personal Health Data Filing System Act of 2002, which emphasizes the importance of 
the individual’s right to privacy. Access to data is only given if their intendent use is 
in accordance with the objectives of the respective registry, often defined by 
authoritative regulations. Approval from the Norwegian Regional Ethical Committee 
is in most instances required, depending on the level of details and anonymity of the 
data enquired.  
The 11-digit personal identification number (PIN), which is unique for every 
individual living in Norway, provides a valuable opportunity of linkage of two or 
more registries, including medical quality registries and national population statistics, 
e.g. regarding education and income. There are four levels of person identification in 
the central health registries provided by NIPH:  
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Anonymous data are data where re-identification of individual persons is made 
impossible. Such data provide the highest level of protection of privacy, but is often 
not adequate when studying rare diseases. Anonymous data are hard to validate, and it 
is not possible to follow individual cases over time, which limits their use. 
Pseudonymous data are data where the identity is encrypted, but each individual has 
been given a person-specific pseudonym, making it possible to follow individuals 
over time. 
De-identified data resembles anonymous data, but the identity may be traced through 
a serial number given each individual. Researchers do not have access to the serial 
numbers, and thus in practice the data may be considered as anonymous. The serial 
number is kept at a trusted third party, usually Statistics Norway, with the purpose of 
facilitating linkage of data. 
Person-identifiable data are data in which each individual’s PIN, or name, or both are 
available to the researcher. Such data are the most extensive for research. Data 
missing the PIN, or name are characterized as person-identifiable if enough personal 
information is included to indirectly identify an individual (‘backdoor-identification’). 
Written, informed consent with a clear statement of the purpose of the research and 
each participant’s rights must be obtained. 
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2. Aims of study 
 
Paper I:  To determine the incidence and prevalence of symptomatic MG in  
  Norway, with emphasize on age- and gender characteristics and  
  geographic variation. 
 
Paper II: To study comorbidity in MG patients, and thereby assessing the total 
  health burden for patients with MG.  
 
Paper III: To assess the clinical course and prognosis of MG, and thereby  
  identifying factors influencing the outcome.  
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3. Materials and Methods 
3.1 Data sources 
The Norwegian Prescription Database (NorPD) 
The NorPD was established in 2004 and is maintained by the NIPH. The database 
contains information on all prescription drugs expedited at every pharmacy in 
Norway, covering the entire population of 5,000,000. The registration is mandatory, 
with monthly automatically generated updates from all pharmacies. The objectives of 
the NorPD are defined in authoritative regulations (‘Forskrift for Reseptregisteret’), 
and data can only be used accordingly; i) to describe patterns of drug use; ii) to form 
basis for research and review of drug safety and effectiveness; iii) for health care 
planning and control; iiii) for quality improvement of prescribing practices.  
In NorPD, the patient’s identity is encrypted, and the unique 11-digit PIN is replaced 
with an encrypted personal-identifier. This personal-identifier is unique for every 
patient, which can be used to follow individuals over time. The information available 
in the NorPD is as follows:  
1. Patient; Encrypted person-identifier, month/year of birth, month/year of death, 
gender, place of residence (municipality and county) 
2. Prescriber; Encrypted person identifier, year of birth, gender, profession, 
medical specialty 
3. Pharmacy; Name, licence number, municipality and county 
4. Drug; Nordic article number (a unique product identifier stating brand name, 
strength, pharmaceutical form and pack size), number of Defined Daily Doses 
(DDD), date of expedition, ATC code, price, prescription category,  
reimbursement code, ICD-10 or ICPC-2 codes (from March 2008, completely 
implemented from March 2009), free text according to pharmacy label. 
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NorPD collects information about prescribed and dispensed drugs at pharmacies to 
individuals living outside institutions. Also included are unlicenced drugs, but not 
drugs sold over-the-counter unless they are prescribed by a physician. For in hospital 
patients, and patients living in nursing homes, drug use is collected on an aggregated 
level, i.e. at the level of the institution or department.194 
Health care in Norway is free of charge for all Norwegian citizens and covers both 
specialist and primary care. For chronic diseases, drugs are reimbursed if the 
diagnosis has been established. For MG, diagnostic workup is performed in specialist 
health care, and Mestinon is reimbursed for all MG patients with an established 
diagnosis (§13).  
Health Regions of Norway 
From 1995 to 2007, the Norwegian Healthcare System was divided into five Health 
Regions. Calculations of the geographical distribution of symptomatic MG assessed 
in paper I was based on these five Health Regions, with a population at prevalence 
day January 1, 2008 of: 916,000 for the Southern Health Region; 1,717,000 for the 
Eastern Health Region; 982,000 for the Western Health Region; 660,000 for the 
Central Health Region; 462,000 for the Northern Health Region.195  
Norwegian Central Population Registry (NCPR) 
The NCPR provides the unique 11-digit PIN since 1960 for all individuals living in 
Norway. The NCPR also register demographic information on the entire population, 
including date of birth, place of residence and date of death or emigration. The 
population in Norway on January 1, 2008 was 4,737,000.195 
Duke MG Patient Database 
Paper III is based on data from the Duke MG Patient Database, which is a physician-
derived registry, containing clinical information on all MG patients treated , both in- 
and outpatients, at the Neuromuscular Clinic at the Duke University Medical Center 
in North Carolina, USA. The registry was established in 1980 and is used for research 
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as well as for evaluating patient outcomes. Patient information is updated after each 
visit by trained nurses (Appendix 1). A written consent is obtained from the patients 
before their clinical information is stored in the registry. The registry is maintained in 
accordance with the Health Information Portability and Accountability Act, the USA 
standards to protect personal health information. All research projects based on data 
from the registry must be approved by the Institutional Review Board of the Duke 
University.196 
As of March 2012, 60 new patients with MG, congenital myasthenic syndromes and 
LEMS were seen at the Neuromuscular Clinic, constituting about 550 clinic visits 
each year. The registry contains information on 1,545 patients with neuromuscular 
disease; 1,310 with MG, 20 with congenital myasthenic syndromes and 110 with 
LEMS.  
 
3.2 Study Population 
Paper I and II 
Data were obtained from the NorPD. All patients using pyridostigmine (Mestinon, 
ATC code: N07AA02), and who fulfilled one of the following criteria were included: 
1.    Minimum two prescriptions of pyridostigmine (Mestinon, ATC code:  
N07AA2) during the study period  
2.     A prescription from a neurologist 
3.     A prescription with a reimbursement code for MG (§13) 
4.     A prescription with an ICD-10 (G70.0) or ICPC-2 (N99) code for MG 
(paper II only) 
In paper I, 723 patients were registered with at least one prescription of Mestinon 
dispensed during the study period from January 1, 2004 - December 31, 2007. Of 
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these, 677 (94%) fulfilled the inclusion criteria. 94% of the final study population had 
a reimbursement code for MG. The remaining 6% did not have an MG specific 
reimbursement code; three patients received a prescription of Mestinon from a 
neurologist; 41 patients had two or more prescriptions of Mestinon dispensed during 
the study period. 
In paper II, 890 patients were registered with at least one prescription of Mestinon 
dispensed during the study period from January 1, 2004 – April 30, 2010. Of these 
830 (93%) fulfilled the inclusion criteria. 89% had either a reimbursement code for 
MG, a prescription with an MG specific code, or a prescription from a neurologist. 
However, the registration of ICD-10/ICPC-2 codes was not fully implemented until 
March 2009.  
Paper III 
All patients treated at the Neuromuscular Clinic at Duke University Medical Center 
from 1980 to 2014 by the same physician, and who had minimum two years of 
follow-up data were included. 268 patients with at least two years of follow up were 
included. Clinical information was complete for 262 patients (98%) at two years of 
follow-up, 213 at five years (80%) and 117 at ten years (44%). Clinical information 
was complete for all 268 patients at their last clinic visit. Some patients with clinical 
information missing at two or five years, but who had information registered at a later 
time point were also included. 
 
3.3 Statistical methods and definitions 
Incidence and prevalence 
Incidence and prevalence were assessed in paper I. Incidence of symptomatic MG 
was defined as all patients who fulfilled one of the criteria preset by us for the MG 
diagnosis during the last year of the study period (2007), and who had no previous 
pyridostigmine prescriptions dispensed the preceding years (2004-2006). Incidence 
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was calculated per one million inhabitants per January 1, 2008. Prevalence of 
symptomatic MG was defined as all patients receiving a prescription with 
pyridostigmine during the study period (January 1, 2004 - December 31, 2007), and 
who were alive and living in Norway at the prevalence date, January 1, 2008. 
Prevalence was calculated per one million inhabitants.  
The Anatomical, Therapeutical and Chemical classification system (ATC) 
All registered drug in the NorPD is classified according to the World Health 
Organization’s ATC classification system, which are structurally divided into groups 
at five levels. At the first level, the drugs are divided into 14 main groups. At the 
second level, the drugs are further divided into pharmacological/therapeutic 
subgroups. The third and fourth levels are the chemical/pharmacological/therapeutic 
subgroups. Finally, the fifth level represents the chemical substance. This system 
makes it possible to compile drug statistics on five different levels.194  
 
Textbox 1: Main ATC groups 
  
A: Alimentary tract and metabolism 
B: Blood and blood forming organs  
C: Cardiovascular system 
D: Dermatologicals 
G: Genito urinary system and sex hormones 
H: Systemic hormonal preparations, exclusive sex 
hormones and insulins 
J: Antiinfectives for systemic use 
L: Antineoplastic and immunomodulating agents 
M: Musculoskeletal system 
N: Nervous system 
P: Antiparasitic products, insecticides and repellants 
R: Respiratory system 
S: Sensory organs 
V: Various* 
 
*The ATC group V (Various) was considered too unspecific 
and therefore not included in the analyses. 
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Total drug treatment of MG patients was assessed by investigating every prescription 
dispensed in all main ATC groups during the study period. In paper II, all main ATC 
groups but one (V: Various*) were assessed (Textbox 1). In addition to the main ATC 
groups, we also assessed various drugs at different ATC levels: A10 (Drugs used in 
diabetes), A10A (Insulins and analogues), H03AA (Thyroid hormones), N05A 
(Antipsychotics), N05B (Anxiolytics), N05C (Hypnotics and sedatives), N06A 
(Antidepressants), N03 (Antiepileptics), C07 (Beta-blocking agents), C08 (Calcium 
channel-blockers), C10 (Lipid-modifying agents) and J01G (Aminoglycoside 
antibacterials).  
Defined Daily Dose (DDD) 
In paper II, the DDDs were assessed to evaluate immunosuppressive drug use in MG 
patients. The DDD is defined as the assumed average maintenance dose per day for a 
drug used on its main indication in adults. The DDD is thus a unit of measurement 
that enables meaningful comparisons between different drugs. The DDDs are 
determined on the basis of evaluation of the use of any specific drug internationally, 
not taking into consideration national therapeutic guidelines which vary between 
countries.194  
Standardized Incidence Ratio 
The standardized incidence ratio (SIR) was assessed in paper II to evaluate the use of 
various drugs according to both the main ATC groups, and also for specific drugs. For 
each subgroup of patients categorised by age and sex, drug statistics for the 
corresponding age and sex groups in the Norwegian population registered in NorPD 
from the same period were recorded. Comparisons of age- and sex-specific drug use 
among MG patients and the Norwegian population were done by comparing the 
observed number of prescriptions for all main ATC groups in the MG patients divided 
by the estimated number of prescriptions for the same drug groups dispensed to a 
similar group, with regard to age and gender, in the general population. 
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Demographic characteristics and outcome variables 
Differences in categorical characteristics of subgroups of MG patients were compared 
by Pearson’s chi-square test. Fisher’s exact test was used for cross-tabulations with 
expected cell count below five. Continuous variables were compared by Student’s t-
test for independent samples or non-parametric tests when comparing more than two 
subgroups, or whenever the distribution was not Gaussian.  
Statistical analyses in paper I and II were performed using SPSS, version 16-21 (IBM 
Corp., Armonk, New York, USA). Statistical analyses in paper III were performed 
using JMP version 11.2 (SAS Institute Inc. Cary, North Carolina, USA). Two-sided p 
values <0.05 were considered statistically significant. 95% CI intervals for SIRs were 
calculated assuming a Poisson’s distribution.  
MGFA Clinical Classification and Post-Intervention Status 
In paper III, the MGFA Clinical Classification and Post-Intervention Status were used 
to assess the clinical course and outcome of MG patients. The MGFA Clinical 
Classification is designed to classify MG patients with similar clinical manifestations 
and disease severity for comparative analyses of different therapeutic interventions,22  
as this is often difficult due to the fluctuating nature of the disease. This 
standardization of grading MG severity is universally accepted and offer more 
precision than the Osserman’s classification of 1958, classifying MG only as mild, 
moderate or severe. The MGFA Clinical Classification defines different levels of 
disease severity according to which muscles are affected (Textbox 2).  
The MGFA Post-Intervention Status (PIS) is designed to assess the clinical state of 
MG patients at any time after treatment has been given.22 Determination of the PIS 
requires that the examination is performed by someone skilled in the evaluation of 
neuromuscular disease. Isolated weakness of eyelid closure is not an exclusionary 
criteria from CSR or PR status, as this was not thought to be a sign of active disease 
by the MGFA Taskforce. Patients receiving AChE-Is, however, are excluded from PR 
or MM-1 status as these medications mask MG symptoms (Textbox 3). 
 53 
 Kaplan-Meier and Cox regression 
In paper III, Kaplan-Meier life tables were used to compare the cumulative chance of 
achieving an optimal outcome in MG and compared by the log-rank test. Variables 
with a significant difference in the Kaplan-Meier model were then adjusted for in the 
Cox regression model for independency and presented as estimated hazard ratios 
(HR) with 95% CI and corresponding p values.  
Textbox 2. MGFA Clinical Classification 
 
Class I Any ocular muscle weakness; may have weakness of eye closure. All other 
muscle strength is normal. 
Class II Mild weakness affecting muscles other than ocular muscles; may also have 
ocular muscle weakness of any severity. 
 IIa. Predominantly affecting limb, axial muscles, or both. May also have 
lesser involvement of oropharyngeal muscles. 
 IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. 
May also have lesser or equal involvement of limb, axial muscles or both. 
Class III Moderate weakness affecting muscles other than ocular muscles. May also 
have ocular muscle weakness of any severity. 
 IIIa. Predominantly affecting limb, axial muscles, or both. May also have 
lesser involvement of oropharyngeal muscles. 
 IIIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. 
May also have lesser or equal involvement of limb, axial muscles or both. 
Class IV Severe weakness affecting muscles other than ocular muscles. May also 
have ocular muscle weakness of any severity. 
 IVa. Predominantly affecting limb, axial muscles, or both. May also have 
lesser involvement of oropharyngeal muscles. 
 IVb. Predominantly affecting oropharyngeal, respiratory muscles, or both. 
May also have lesser or equal involvement of limb, axial muscles or both. 
Class V Defined as intubation, with or without mechanical ventilation, except when 
employed during routine postoperative management. The use of feeding tube 
without intubation places the patient in class IVb. 
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Textbox 3. MGFA Post-Intervention Status (modified version). 
 
CSR The patient has had no symptoms or signs of MG for at least 1 year and 
has received no therapy for MG during that time. There is no weakness of 
any muscle on careful examination by someone skilled in the evaluation 
of neuromuscular disease. Isolated weakness of eyelid closure is accepted. 
PR The same criteria as for CSR except that the patient continues to take 
some form of therapy for MG. Patients taking cholinesterase inhibitors are 
excluded from this category because their use suggests the presence of 
weakness. 
MM No symptoms of functional limitations from MG but has some weakness 
on examinations of some muscles. This class recognizes that some 
patients who otherwise meet the definition of CSR or PR do have 
weakness that is only detectable by careful examination. 
MM-0 The patient has received no MG treatment for at least 1 year. 
MM-1 The patient continues to receive some form of immunosuppression but no 
cholinesterase inhibitors or other symptomatic therapy. 
MM-2 The patient has recived only low-dose cholinesterase inhibitors (<120 mg 
pyridostigmine/day) for at least 1 year. 
MM-3 The patient has received cholinesterase inhibitors or other symptomatic 
therapy and some form of immunosuppression during the past year. 
 Change in status 
Improved A substantial decrease in pretreatment clinical manifestations or a 
sustained substantial reduction in MG mediations as defined in the 
protocol. 
Unchanged No substantial change in pretreatment clinical manifestations or reduction 
in MG medication as defined in the protocol.  
Worse A substantial increase in pretreatment clinical manifestations or a 
substantial increase in MG medications as defined in the protocol. 
Exacerbation Patients who have fulfilled criteria of CSR, PR or MM but subsequently 
developed clinical findings greater than permitted by these criteria. 
Died of MG Patients who died of MG, of complications of MG therapy, or within 30 
days after thymectomy. 
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4. Results 
4.1 Paper I 
The study included 435 (64%) women, 242 men, with an overall female to male ratio 
of 1.8. Point prevalence (January 1, 2008) of symptomatic MG was 131 per million; 
92 for men, 170 for women. Mean age of prevalent MG patients was 56 years, 60 
years for men and 54 years for women. Female to male ratio in the age group <50 
years was 3:1 compared to 1.5:1 in the age group t50 years. For those <50 years, the 
point prevalence was 67 per million, and 258 per million for patients t50 years. The 
peak prevalence for both genders was around 70–79 years. The number of female MG 
patients increased steadily up to 70–79 years, while the number of male patients rose 
sharply after the age of 50 years. 
74 new users of pyridostigmine were registered in 2007 (42 women, 32 men). The 
incidence rate of symptomatic MG for the year 2007 was 16 per million; 14 for men, 
18 for women. Mean age of incident cases was 59 years; 64 and 55 years respectively. 
Both prevalence and incidence was higher in the age group ≥50 years than <50 years, 
and highest at 70–79 years. The rates were stable for both men and women until age 
60 years, with a small peak for women at age 30–39 years. The highest rate for both 
genders was at 70–79 years. Incidence for patients <50 years was 7 per million. 
Patients t50 years had an incidence of 34 per million. Prevalence and incidence did 
not differ in the five geographical health regions in Norway.  
4.2 Paper II 
In this study, we evaluated the total drug treatment of MG patients, with comparisons 
to the general population, in the period from January 1, 2004 to April 30, 2010. 
87,556 prescription medications were in total dispensed to 830 MG patients. Only 19 
individuals (2.3%) received no other medication than Mestinon. The remaining MG 
patients received all types of medication, and more often than compared to the general 
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population in nearly all categories of drugs. Most frequent were drug therapies for the 
Alimentary tract and metabolism, Systemic hormonal preparations and Antineoplastic 
and immunomodulating agents.  
Comedication with insulins was almost three times more frequently prescribed to MG 
patients ≥50 years, both males and females, compared to the general population. 13% 
received thyroid hormone therapy, most frequently MG patients <50 years and male 
MG patients compared to patients ≥50 years and female MG patients, and twice as 
often as the general population. 29% received treatment with hypnotics and sedatives, 
and twice as often given as for the general population for the age group <50 years. 
21% received antidepressants; twice as often given to male MG patients than to the 
male population. 20% received anxiolytics, while 7% received antipsychotics, with 
the same frequency in MG patients as in the general population. MG patients were 
more often treated with antiepileptic drugs, calcium-channel blockers and lipid-
modifying agents, and with the same frequency as in the general population with beta-
blocking agents. All four drug groups were given more frequently to MG patients <50 
years compared to the general population at the same age.  
The DDDs of pyridostigmine were lower for MG patients <50 years compared to 
those ≥50 years. There was no difference between males and females. Less DDDs of 
immunomodulating agents were prescribed to MG patients <50 years and females 
compared to MG patients ≥50 years and males. 406 MG patients (49%) did not use 
any immunosuppressive drugs during the study period. Patients <50 years were 
prescribed less DDDs of prednisolone compared to patients ≥50 years. No such age 
difference was seen for azathioprine. Females were prescribed less DDDs of both 
prednisolone and azathioprine compared to males. 
 4.3 Paper III 
The study included 197 patients with elevated AChR-antibodies (74%), 13 with 
MuSK-antibodies (5%) and 58 who were double negative (22%). There were some 
distinct clinical features related to antibody status; AChR-positives were more often 
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late onset, male and white, compared to MuSK-positives, who had early onset, were 
more often female and African-American. Patients without AChR- or MuSK-
antibodies were more often early onset, male and white. Thymectomy was performed 
in 110 patients, and at different rates among the antibody groups (p=0.02). Over 50% 
of MuSK-positives were thymectomized, compared to 26% of the double negatives 
and 45% of AChR-positives. All 22 patients with a thymoma were AChR-positive. 
There was no difference among the antibody groups regarding reported thymus 
histology. 
56% of the study population had moderate or severe weakness at maximum, and only 
13% had purely ocular manifestations at least two years after onset. Maximum 
weakness differed among the antibody groups (p<0.001), with MuSK-positives being 
less often purely ocular compared to AChR-positives and double negative patients. 
Clinical severity was different among the antibody groups at two (p=0.02) and five 
years of follow-up (p=0.02) and at the last clinic visit (p=0.005), but not after ten 
years, probably because too few patients were followed that long. At two years, 30% 
of the AChR-positives, 26% of the double negatives, and only 15% of the MuSK-
positives were in remission. MuSK-positive patients had more severe weakness at 
initial presentation, but the majority had mild weakness throughout the subsequent 
follow-up period. The rate of spontaneous remission in the total patient cohort was 
1%.  
Outcomes did not differ among the different antibody groups at any time point. After 
two years, 65% had achieved an Optimal outcome; 73% did so after five years; and 
75% after ten years of follow-up. Only 3% had a Poor outcome after ten years. The 
probability of achieving an Optimal outcome did not differ among the antibody 
groups at any time point. Most consistently, age at onset, thymectomy and disease 
distribution at maximum severity differed regarding the probability of achieving an 
Optimal outcome at each time point. However, after adjusting for these variables in 
the Cox model, only onset after age 50 years independently predicted an Optimal 
outcome at each time point.  
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5. Discussion 
5. 1 General discussion 
Epidemiology 
We demonstrate that MG incidence and prevalence is higher than previously 
expected, especially in the elderly. Our estimated incidence of 16 per million is in line 
with most previous reports of MG incidence, with the highest reported incidence so 
far being 24.9 per million.29 Also, this rate is comparable to MG incidence found in 
prospective studies and other population-based studies. Furthermore, we found that 
the increase is particularly profound in the elderly, both men and women, as shown 
also by others.40;41 There are several factors that might explain this development: First 
and foremost, improved diagnostic accuracy and case ascertainment have had a major 
impact. After the AChR-antibody assay was introduced and commercially available 
around the mid-1980s, the incidence rates near doubled.25 Second, the demographic 
pattern is shifting towards an aging population at higher risk of acquiring the disease, 
possibly due to age-related alterations of the immune system.197 At the same time, the 
birth rates are declining. Third, unknown environmental factors, lifestyle changes or 
genetics factors may cause increased susceptibility leading to an increased incidence. 
Our prevalence rates of 131 per million is comparable with other population-based 
studies and in line with previous studies on MG prevalence. Over the past six 
decades, MG prevalence has risen from less than 30 per million42 to over 300 per 
million in 201443 as a consequence of increasing incidence and longevity of MG 
patients. In Norway, the reported prevalence has increased from 21 per million in 
195142 to 90 per million 30 years later34. Another three decades later, the prevalence 
of MG in Norway is around 130-145 per million.44;45 A similar development in 
prevalence was found in Italy; from 83 to 130 per million over a period of 20 years.41 
In addition to factors influencing incidence and mortality, these differences in 
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prevalence also most likely reflect better access to specialized health care and 
increased awareness of the disease among neurologists and physicians. 
In paper I, we found that prevalence and incidence were higher in the age group >50 
years than <50 years. MG onset after the age of 50 years used to be considered rare.46 
During the 1990s, epidemiological data suggested that MG is occurring more 
frequently in older individuals than previously believed. Peak age at onset reflect 
these differences in incidence between the two genders (Figure 2). In females, the 
peak occurs in the second and third decade of life, while the peak is in the sixth and 
seventh decade in males. In some countries, with a particular Scandinavian cluster, 
there is a bimodal distribution of onset in females with a peak in the sixth and seventh 
decade as well.25;41;44;45;100;198 More recently, only one peak of age at onset has been 
demonstrated in both genders, usually around the seventh and eighth decade.28-30 In 
light of these recent findings, it is likely that older individuals, both males and 
females previously have been grossly underdiagnosed.46;199  
As Somnier et al pointed out in the early 1990s, the subgroups EOMG and LOMG 
may be different entities of MG altogether.38 The thymus in EOMG patients is often 
hyperplastic with lymphocytic infiltrates and germinal centers similar to those found 
in lymph nodes. All components necessary for developing an immune response are 
present and can support an intrathymic pathogenesis for the immune response in 
EOMG. These thymic abnormalities are usually lacking in LOMG. The mechanisms 
of autosensitisation to AChRs in this subgroup are unclear. Other striking differences 
between EOMG and LOMG are the HLA-profile, titers of circulating AChR-
antibodies, presence of striated muscle antibodies and associated autoimmune 
comorbidity. Interestingly, several studies, including ours, report a peak age of MG 
incidence around 70-80 years, with an abrupt fall in incidence in the age group >80 
years.44;45;199;200 Important clinical features in MG such as ptosis, diplopia and facial 
muscle weakness are more easily overlooked in the elderly as ageing causes sagging 
of the lower eyelids and weaker tonus of the facial muscles.46 Another factor is the 
competing risk for developing other fatal diseases for those patients at risk for 
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developing MG.199 In our study, only patients living outside institutions were 
included. That means that about 19% of the population >80 years are not accounted 
for. The rate of MG among the population in this age group living in institution is 
unknown. 
Comorbidity 
Our findings show that comedication in MG is widespread, requiring more frequent 
drug treatment for several major disease groups than in the general population. 
Cardiovascular drug therapy is more often given to MG patients compared to the non-
MG population. The possibility for cardiac involvement in MG is well recognised; 
MG-specific cardiac muscle antibodies and reactive cardiac autoantibodies have been 
described, and minor cardiac dysfunctions have been demonstrated by functional 
imaging studies.176-178 The clinical implications of these findings remain unclear. 
Nevertheless, our data indicate that there is a clinically relevant association between 
MG and cardiovascular disease. Death from cardiac diseases, however, is not 
increased in MG patients.23;201 
In our study, insulins and thyroid substitution therapy functioned as proxies for 
autoimmune disease. We found that both these types of comorbidities are elevated in 
MG. The risk of a second autoimmune disorder is increased in MG patients compared 
to non-MG, more frequently in EOMG, but also to some degree in LOMG compared 
to non-MG population.171 Previous studies have identified autoimmune thyroid 
disease, SLE, diabetes mellitus and rheumatic arthritis as the most frequent 
autoimmune disorders associated with MG.172  
The risk of severe respiratory tract disease is increased in MG,23 in addition to the 
increased risk of infections in general due to immunosuppressive treatment.142 
Infections may precipitate MG worsening, and should be treated aggressively, 
especially of the respiratory tract, as respiratory muscle weakness may lead to 
myasthenic crisis.171 This probably explains why antiifectives is more often used in 
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MG compared to the general population. Death due to respiratory disease in MG is 
near normal level.23  
Outcomes 
Surprisingly, we found that MG onset after the age of 50 years increased the chances 
for an Optimal outcome. This is in contrast to previous similar studies where a late 
onset was associated with a worse prognosis.21;191 There is a potential referral bias to 
our clinic towards patients with more severe disease, but this bias is expected to be 
the same for all age groups. It is probable that elderly patients are more aggressively 
treated at our clinic: 87% of the patients over 50 years were treated with an 
immunosuppressive agent, either alone, or in combination with another treatment 
modality, in contrast to 56% of Norwegian MG patients over 50 years.44 However, 
this comparison is complicated by the potential selection bias in patients seen at a 
specialized University clinic in contrast to the unselected Norwegian cohort which is 
based on the entire population. 
Although the clinical distribution at maximum weakness differed among the three 
antibody groups, we did not find any difference in the chance of achieving an Optimal 
outcome for mild/moderate compared to severe disease. MuSK-MG is characterized 
by rapid deterioration early in the course of disease with generalization usually 
occurring within the first month. The MuSK-positive patients in our study had more 
severe disease than AChR-positives and the double negatives. Nevertheless, the 
majority of these patients achieved an Optimal or Intermediate outcome, a similar 
long-term prognosis as AChR-positive patients, in accordance with previous 
studies.21;202  
Thymectomy was performed both in double negative and MuSK-positive patients. 
The role of thymectomy in these two groups is still unclear, with conflicting evidence. 
Only one of our thymectomized MuSK-positive patients was in CSR at last visit; this 
rate, however, was comparable to thymectomized AChR-positive and double negative 
patients. Univariate analysis at all time-points clearly indicates that thymectomy is 
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associated with MG outcome. However, the thymectomized patients represent a 
selection bias towards more severe disease, including thymoma patients. This could 
explain why thymectomy does not independently predict outcome after adjusting for 
age at onset and clinical severity.  
 
5.2 Methodological considerations 
5.2.1 Study design 
Paper I and paper II are cohort studies based on observational data from a population-
based prescription register. NorPD covers the entire population, thus enhances 
statistical power and minimizes selection bias. The information collected is nearly 
complete, and is less prone to information bias and other types of systematic errors. 
Population-based cohort studies also include a wider range of disease severity among 
the study subjects than other more selected study samples and study designs. 
Furthermore, Norway has a relatively homogeneous and a stable population, with low 
rates of emigration. A population-based cohort study design performed in a stable 
genetic ‘pool’ is thus suitable for epidemiological research in general and for rare 
diseases especially.  
Although complete, the information in population-based registers is often limited as 
they may be designed for other purposes, e.g. administrative purposes. Relevant 
clinical information desired by researchers may be difficult to obtain, or are missing. 
For NorPD, drug compliance is not known. Also, the indication of drug prescribing 
was until March 2009 incomplete. There are two main indications for Mestinon in 
Norway; MG and gastrointestinal dysmotility. MG patients are reimbursed with a 
specific reimbursement code which functions as a proxy of diagnosis. However, the 
drug is relatively inexpensive, and reimbursement may be declined by some patients. 
The efficacy of Mestinon in treating gastrointestinal dysmotility in diagnosis such as 
chronic intestinal pseudo-obstruction is inconclusive.203 Mestinon can also be used as 
supplementary agent when treating orthostatic hypotension. Evidence of the efficacy 
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of this treatment is limited.204;205 Information on drug use for patients living in 
institutions is not available in NorPD. These include many elderly. In 2013, 14% of 
the Norwegian population over 80 years lived in institutions.206  
Paper III is based on a physician-derived registry containing clinical patient 
information. Such patient registries are useful in several ways. First, they contribute to 
optimizing management of the patient by facilitating evaluation of therapy response. 
In clinical research, information can be used to assess patient outcome. Public health 
reporting, geographic surveys, epidemiological research are other ways of utilizing 
such information. The Duke MG Patient Database is designed to achieve these goals 
by systematically collecting data and regularly updating the information after each 
patient visit. Data entry is performed by the physician or other trained personnel 
(nurses, residents), and the registry is continuously developed in accordance with the 
latest standards of clinical assessments.196  
As with all hospital-based materials, data are subject to selection bias, and the disease 
severity among the study population may not be representative. Referral bias is 
another potential problem for medical centers with an expertise in specific fields. In 
countries without universal health care coverage, such as the USA, studying disease 
severity in specific social classes may not be possible with data from patient registries 
as entry requires a health insurance, which is often financed through employment.  
 
5.2.2 Internal validity 
Internal validity refers to the accuracy or precision of the measured parameters in a 
study and is dependent on the degree of error in the measurement. Errors in 
epidemiological research are either random or systematic.  
Random errors and precision 
Data collection, coding and analysis are subjects of random errors, causing variations 
around a true value. Random errors are thus a problem of precision. A precise 
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estimate is an estimate with little random error. Large study samples reduce the effect 
of random errors, thus enhancing the precision of the study. The precision of an 
estimate is further indicated by the CI, i.e. the statistical variation, or random error, 
underlying the estimate. A narrow CI reflects a high precision of the estimate.  
NorPD is a nationwide database covering about five million people. Since the 
establishment in 2004, 96% of the entire Norwegian population has been included in 
NorPD with at least one prescription drug dispensed from a pharmacy. The one year 
prevalence of 68-69% has also been stable.194 Such a large study size reduces the 
effects of random errors. Furthermore, data collection is generated automatically 
every month from the pharmacies to NorPD, thus avoiding extra work for the 
pharmacy. Coding errors or inconsistencies are systematically searched after by the 
NIPH before transferring data to NorPD. NIPH routinely checks if the data deliveries 
from each pharmacy seem to be reasonable. Any unusual fluctuations in size of data 
files from one month to another are identified. Missing data are also checked for, such 
as empty data files due to technical errors at the pharmacy. Every month, the total 
number of prescription records and the number of patients and prescribers are 
checked.  
The Duke MG Patient Register is controlled at every single registration by the 
examining physician, and records are updated by a trained nurse. There is no 
systematic quality control, but the register is widely used for clinical assessment of 
patients and for research, and is controlled whenever data is extracted. 
Systematic errors and validity 
Systematic errors, or bias, occur when the true value is different from the observed 
value due to any other cause than random variability.  A valid estimate is thus an 
estimate with little systematic error. Systematic errors are not affected by increased 
study sample.207 Three main types of systematic errors can affect the internal validity: 
Selection bias, information bias and confounding. 
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The validity of a diagnostic test or statistical method is described by its sensitivity and 
specificity. Sensitivity refers to the proportion of actual positives that are correctly 
identified, i.e. true positive. In paper I and II, the sensitivity of using prescription of 
Mestinon to identify MG patients, reflects the percentage of Mestinon users with an 
MG diagnosis as defined by us. Specificity refers to the proportion of actual 
negatives, according to our definition, that are correctly identified, i.e. true negative. 
The validity of a test can also be expressed by its predictive value. The predictive 
value refers to the probability that a person who is categorized as positive, or 
negative, has or will develop the disease. In Norway, Mestinon is used by nearly all 
MG patients with a symptomatic disease,208 and is in principle reimbursed to MG 
patients only. However, Mestinon is used by some patients with LEMS, and these 
would be reimbursed as for MG. Nevertheless, LEMS is extremely rare, with a 
prevalence of 2-3 per million.79 3,4-diaminopyridine is the first choice for 
symptomatic treatment of patients with LEMS. Pyridostigmine is mostly used when 
3,4-diaminopyridine is not available.79 
In paper II we performed analyses according to the different criteria for inclusion. 
Using the strictest criteria for MG (reimbursement code for MG only), yielded the 
lowest number of MG patients. Combining the three criteria highly specific of MG 
yielded the second highest number of MG patients. Our method of identifying MG 
patients has a high sensitivity which is lacking from other more selected populations, 
especially for patients without AChR- or MuSK antibodies.  
When comparing data from a national database on AChR-antibody assays with data 
from NorPD, the estimated prevalence rates are in good concordance. However, the 
incidence rates were higher with NorPD data than the AChR-antibody assay database, 
even after a calculated estimate of 15% of MG patients without detectable AChR-
antibodies.27 The comparison was made between MG patients with a symptomatic 
disease (identified in the NorPD) and patients with a positive AChR-antibody assay. 
These two groups are not identical as the AChR-antibody assay database only 
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includes patients with AChR-antibodies, while NorPD includes all MG patients both 
with and without AChR-antibodies.  
The Danish authors, Pedersen et al, validated a method for identifying MG patients by 
linking two automated registers available in Denmark; The Danish National Hospital 
Register (Patient Register) based on MG specific codes generated from hospital 
contacts, and the Regional Prescription Register based on prescriptions of 
pyridostigmine. The MG diagnosis was then verified by reviewing medical records. 
The results from a national Danish AChR-antibody register were also linked. The 
authors concluded that subjects identified in the Patient Register were comparable 
with subjects found in the Prescription Register with regard to age and gender, but 
that the former were more often seropositive. The proportion of false positives was 
about 10 %, similar for all three registries. The sensitivity for the Prescription 
Register only was 88%, with a PPV of 80%.209 As the Norwegian and Danish 
healthcare system are comparable, and the structure of both the Patient and 
Prescription registries in the two countries are essentially similar,210 we believe that 
these results are generalizable to Norway, and that using pyridostigmine prescriptions 
registered in NorPD is a valid method to identify MG patients. 
 
5.2.3 Selection and information bias 
Selection bias 
Selection bias stems from factors that influence study participation and procedures 
used to select study subjects. If the exposure-outcome associations in a study are 
different for those who participate compared to non-participants, the effect estimates 
in the study will differ from that of the general population.207 Self-selection bias 
refers to a situation where background characteristics interfere with an individuals’ 
decision to participate, threatening the validity of the results because the reasons for 
participation may be associated with the study outcomes.  
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The compulsory inclusion of all prescriptions expedited in Norway during the study 
period excludes the possibility of self-selection bias in paper I and II, providing a 
highly representative population. Data from NorPD are collected systematically and 
covers the entire population. The risk of selection bias is therefore nonexistent. A 
diagnostic workup of MG is carried out in specialist health care. In Norway, the 
citizens have free choice of hospital, but only about 1% of patients are treated by 
other hospitals than their default hospital. In paper III, data collection is based on 
patients who are treated at one specific hospital, and the risk of selection bias is 
therefore higher. 
Information bias 
Information bias arises due to erroneous measurement of the exposure or outcome 
variables under study. The term misclassification is often used for information bias 
that applies to categorical variables, and the error leads to a person being placed in an 
incorrect category. Misclassification of subjects can be either differential or non-
differential. Differential misclassification occurs when incorrect classification of a 
variable depends on the value of other variables.207 Such misclassification can either 
exaggerate or underestimate the effects in a study. Non-differential misclassification 
arises when incorrect classification of a variable is unrelated to other variables.207 
This tends to dilute the true difference between groups in a study.  
Registration errors in large registries such as NorPD are inevitable. Most likely, such 
errors are non-differential and would result in too low effect-estimates for the MG 
population. Misclassification due to wrongly assigned diagnosis code (ICD/ICPC) on 
the prescription is possible, but highly unlikely as Mestinon is mainly indicated for 
MG only. However, ex juvantibus prescribing may occur. Misclassification may also 
be introduced by the observer (interviewer bias, follow up bias), or by the study 
participants (recall bias). In NorPD, these types of biases are nonexistent. In the Duke 
MG Patient Register, both differential and non-differential misclassifications are 
possible. First, the information is based on the physician’s clinical examinations, 
which may vary. The MGFA clinical classification and PIS scoring are dependent on 
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what the patient tells the physician (recall bias), and how the physician formulated the 
questions (interviewer bias). In our study, only data from patients treated by one 
single physician were obtained, minimizing these types of biases as data would be 
obtained in a consistent manner from a highly trained specialist in MG.  
 
5.2.4. Confounding 
Confounding arises when a third factor partly or fully explains the observed 
association between the exposure and the outcome. Confounding can be regarded as a 
confusion, or mixing, of effect, and failure to account for such factors can result in 
spurious associations. Randomization, multivariate adjustment, stratification and 
matching are common methods used to control for possible confounders. 
Confounders in paper II are age and gender; females traditionally are younger at 
disease onset than males. Age and gender were adjusted for in a linear regression 
model in paper II. In paper III, age, gender and disease severity are potential 
confounders and were adjusted for in the Cox regression model. 
 
5.2.5. External validity 
External validity is the extent to which the results can be generalized to other settings. 
NorPD does not contain data on MG patients so that they could be classified into the 
distinct MG subgroups, such as LOMG and thymoma MG and with varying non-
AChR antibody status. Comprehensive subgroup analyses were not possible for paper 
I and II as this information was not available in the database. However, as paper I 
aimed to assess incidence and prevalence of symptomatic MG, we believe that the 
results from this study are applicable to other populations because of the large, 
unselected cohort. In paper II, we do not know whether specific drug use is associated 
with specific MG subgroups. Furthermore, there are some genetic heterogeneity in the 
population with about 15% immigrants and children of immigrant parents, and an 
estimated Sami population of about 55 000 (approximately 1%).  
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In paper III, subgroups of MG were assessed. North-Carolina has a population of 
9,943,964 inhabitants, consisting of 65% whites, 21% African-Americans, 8% 
Hispanics and 2% Asians. About 16% do not have a health insurance, which is the 
same rate as for the whole of the USA.211  
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6. Conclusions  
Paper I: Our calculated prevalence and incidence is in agreement with other 
population-based studies. There were no geographical differences in prevalence and 
incidence in Norway.  
Paper II: MG patients are more often treated with non-MG prescription drugs for 
nearly all groups of medication compared to the general population. These findings 
reflect frequent comedication and comorbidity. 
Paper III: The prognosis of MG, both short- and long-term, is favorable for the 
majority of patients, regardless of age, maximum disease severity and antibody status. 
MG is one of the best studied and understood autoimmune diseases in humans. The 
unravelling of the pathophysiology of MG with application for diagnosis and therapy 
has had major impact on the prognosis of MG, as well as serving as a model for other 
autoimmune diseases. Although our knowledge of the underlying mechanisms of the 
disease is well understood, the etiology remains a mystery.  Epidemiological studies 
are one way of studying etiology. Describing disease frequency, analyzing time 
trends, presenting case characteristics are important pieces in the puzzle in 
understanding the etiology of a disease. Epidemiological studies ultimately seek to 
improve prognosis by controlling the spread of the disease and reducing mortality; all 
of which are elements discussed in this thesis. 
A crucial factor in conducting epidemiological research is case ascertainment devoid 
of selection bias. Population-based epidemiological studies on MG are rare. By using 
a nationwide, compulsory registry, this research has contributed to further knowledge 
of the true epidemiology of this rare disease. Assessments of comorbidity and drug 
treatment have elucidated the total disease burden of MG. By using a longitudinal, 
comprehensive patient registry to identify prognostic factors, this work should help 
guide treatment decisions and thereby enhancing a favorable outcome in MG. 
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Errata 
Paper I: 
In Methods, prevalence day should be 1 January 2008 (not 1 January 1 2008). 
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Background: Pyridostigmine is the ﬁrst drug of choice for patients with myasthenia
gravis (MG). The drug is not prescribed regularly to any other patient groups. We
aimed to determine the prevalence, incidence and gender-speciﬁc characteristics of
patients with MG needing drug treatment in a well-deﬁned population cohort.
Methods: Data were retrieved from the Norwegian Prescription Database (NorPD)
2004–2007, containing information on all dispensed drugs in Norway. The study
population comprised 677 recipients of pyridostigmine who met the following inclu-
sion criteria (one or more): (i) More than one prescription 1 January 2004–31
December 2007, (ii) prescription from a specialist in neurology, (iii) prescription for
MG being speciﬁed in NorPD.
Results: A total of 435 (64%) women and 242 men were included; female:male ratio
1.8:1. Point prevalence (1 January 2008) of symptomatic MG was 131 per million; 92
for men, 170 for women. Seventy-four new users of pyridostigmine were registered in
2007 (42 women, 32 men), i.e. the incidence rate for 2007 being 16 per million; 14 for
men, 18 for women. Mean age of incident cases was 59 years; 64 and 55 years,
respectively. Prevalence and incidence were signiﬁcantly higher in the age group
‡50 years than <50 years (P < 0.001), and highest at 70–79 years. Prevalence and
incidence did not diﬀer in the ﬁve geographical health regions in Norway.
Conclusions: Reported prevalence and incidence are amongst the highest found in
similar studies. This may be explained by optimal case identiﬁcation, higher incidence
of drug requiring MG amongst the elderly, and recurrences of previous MG.
Introduction
Autoimmune myasthenia gravis (MG) is caused by
pathogenic antibodies directed at the acetylcholine
receptor (AChR) on the post-synaptic muscle mem-
brane endplate, leading to loss of functional AChRs.
A small minority of patients with MG have instead
antibodies against a kinase, MuSK, in the post-synaptic
membrane. More than 90% of MG patients with gen-
eralized disease have detectable antibodies in their sera
[1]. Clinical manifestations with increased fatigability in
skeletal muscles are attributed to the less eﬀective
neuromuscular transmission. Symptomatic treatment
for patients with MG is managed by inhibiting the
action of acetylcholine esterase at the neuromuscular
junction. Low-aﬃnity antibodies to the AChR were
recently detected in some seronegative patients [2],
explaining the similar clinical presentation and eﬀect of
anti-acetylcholinesterase agents in seropositive and
seronegative MG. Pyridostigmine, an acetylcholine
esterase inhibitor, is the recommended drug to all
patients with MG as the ﬁrst line of therapy [3,4].
Increasing MG prevalence and incidence are evident
during the past decades [5,6]. Most epidemiological
studies are regional- or hospital-based, whilst nation-
wide population-based cohort studies are rare [7,8]. Our
study provides epidemiological data covering an entire
country by means of the Norwegian Prescription
Database (NorPD). In Norway, pyridostigmine is pre-
scribed regularly only to patients with MG, and only to
those requiring symptomatic treatment. Therefore,
pyridostigmine prescriptions recorded in NorPD rep-
resent a reliable method for epidemiological analysis of
both seropositive and seronegative MG that are active,
i.e. with ongoing symptoms.
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Our main objectives were to report the prevalence
and incidence of active, symptomatic MG, and to
present gender- and age-speciﬁc characteristics amongst
patients with MG requiring drug treatment in Norway.
Methods
Norwegian Prescription Database was established in
2004 and is based on the mandatory registration of all
prescription drugs dispensed at pharmacies in Norway.
The database covers the whole population of
4.7 million inhabitants (1 January 2008, Statistics
Norway-SSB, http://www.ssb.no). All registered drugs
are classiﬁed according to the Anatomical Therapeutic
Chemical (ATC) Classiﬁcation System. Patients and
prescribers identity are concealed and replaced with
individualized pseudonyms, making it possible to
follow each person over time.
Data drawn from NorPD comprised all prescriptions
of pyridostigmine dispensed between 1 January 2004
and 31 December 2007. The following variables were
examined: Patients sex, age and county of residence,
information about the drug, including brand name,
size, number and strength of packages dispensed, date
of purchase and ATC code (N07AA02). Whether the
prescriber was a specialist in neurology or not was also
noted. For chronic conditions, a reimbursement code
will be recorded. This code may function as a proxy of
diagnosis.
All 723 individuals who had at least one prescription
of pyridostigmine dispensed during 2004–2007 were
initially included. To ensure the inclusion of patients
with established and active MG only, a requirement for
ﬁnal inclusion was more than one prescription in the
time period, prescription by a specialist in neurology, or
prescription for MG being speciﬁed in NorPD. This left
677 patients representing our study population. Of
these, 633 (94%) had an MG reimbursement code. For
the remaining 44 patients (6%), three received a pre-
scription from a specialist in neurology, whilst 41 had
two or more prescriptions of pyridostigmine during the
study period.
As prevalence day, 1 January 1 2008 was selected. All
population ﬁgures were obtained from Statistics Nor-
way. Incidence and prevalence rates were calculated per
million inhabitants. The prevalence of MG patients
with symptomatic treatment was deﬁned as the number
of patients who had received a prescription of pyrido-
stigmine as described above and were alive, living in
Norway on prevalence day according to NorPD. Inci-
dence of patients with MG requiring symptomatic
treatment was deﬁned as new users of pyridostigmine.
Incidence could be determined for 2007 only and was
ascertained by identifying all individuals who received
pyridostigmine for the ﬁrst time in 2007, and who had
no pyridostigmine dispensed during 2004–2006.
The geographical distribution of symptomatic MG
was calculated by examining pyridostigmine prescrip-
tions from pharmacies belonging to the respective
health regions according to the regional division of the
Norwegian healthcare 1995–2007.
Background variables were compared using cross-
tables with Pearson chi square test. Two-sided P values
£0.05 were interpreted as signiﬁcant. Ninety-ﬁve per
cent conﬁdence intervals (95% CI) were calculated
assuming a Poissons distribution. The statistical anal-
yses were performed in SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Prevalence
On 1 January 2008, a total of 619 patients with MG
(216 men, 403 women) were receiving symptomatic
treatment, female:male (F:M) ratio 1.8:1. This repre-
sents a prevalence of 131 per million (95% CI 123–144),
92 for men (95% CI 83–108), and 170 for women (95%
CI 154–187).
Mean age of all patients with MG prevalent was
56 years (95% CI 55–58 years), 60 years for men (95%
CI 58–62 years) and 54 years for women (95% CI 52–
56 years). Female: male ratio in the age group
<50 years was 3:1 compared to 1.5:1 in the age group
‡50 years. For those <50 years, the point prevalence
was 67 per million (95% CI 59–77), whilst for patients
‡50 years the point prevalence was 258 per million
(95% CI 240–291). When comparing the prevalence for
the two age groups <50 years and ‡50 years, a signif-
icant diﬀerence was found both for the two sexes
combined (P < 0.001), and for men and women sepa-
rately (P < 0.001).
The peak prevalence for both sexes was found in the
age group 70–79 years (Table 1). The number of female
pyridostigmine users increased steadily up to 70–
79 years, whilst the number of male users rose sharply
when reaching the age group 50–59 years (Fig. 1a). The
prevalence was lowest in the northern region. When
comparing the prevalence in the ﬁve geographical
health regions in Norway (P = 0.4), no signiﬁcant
diﬀerence was detected.
Incidence
A total of 74 individuals (32 men, 42 women) obtained
their ﬁrst pyridostigmine prescription in 2007. There-
fore, total incidence rate for 2007 was 16 per million
(95% CI 12–19), 14 for men (95% CI 9–19) and 18 for
2 J. B. Andersen et al.
 2010 The Author(s)
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women (95% CI 12–23). Figure 1b shows stable low
rates for both men and women until the age of 60, with
a small peak for women at the age group 30–39 years.
The highest rate of new users of pyridostigmine was for
both sexes combined in the age group 70–79 years.
Mean age of incident cases was 59 years (95% CI 55–
64 years); 64 years for men (95% CI 58–71), and
55 years for women (95% CI 49–61). Incidence for
patients <50 years was 7 per million (95% CI 4–10).
Patients ‡50 years had an incidence of 34 (95% CI 25–
43). This diﬀerence was highly signiﬁcant (P < 0.001).
The age- and sex-speciﬁc incidence rates of symptom-
atic MG in Norway are summarized in Table 2. Lowest
incidence was found in the northern region. TheT
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Figure 1 Age and sex speciﬁc distribution of symptomatic
myasthenia gravis in Norway. (a) prevalence, (b) incidence.
Circles = women; triangles = men. Rates are per million
inhabitants.
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incidence rates did not diﬀer signiﬁcantly in the various
parts of Norway (P = 0.09).
Discussion
In this large, population-based cohort study on symp-
tomatic MG in Norway, we present for the ﬁrst time
prevalence and incidence of drug requiring MG. Our
study had several strengths. This represents the ﬁrst
epidemiological study on both seropositive and sero-
negative active MG encompassing a whole population.
A complete case ascertainment was achieved by
obtaining data from a national health registry. This
method enhanced power whilst minimizing bias. Fur-
thermore, pyridostigmine being the only non-immuno-
suppressive drug providing symptomatic relief for both
seropositive and seronegative MG is a speciﬁc and
sensitive indicator for MG requiring drug treatment.
Studies on Norwegian MG cohorts report pyridostig-
mine consumption in nearly all cases [9–11]. Therefore,
pyridostigmine use should be considered as a reliable
surrogate marker for active MG. Some patients with
Lambert-Eaton myasthenic syndrome (LEMS) or con-
genital myasthenia may use pyridostigmine. Some
patients with milder symptoms, especially ocular cases,
may not use pyridostigmine. These two sources of error
count in opposite directions and should only marginally
inﬂuence the ﬁnal results.
The prevalence rate of 131 per million found in this
study is comparable to the highest observed in recent
studies from other parts of the world, the top ranging
from 142 [12] to 175 per million [13]. An incidence rate
of 16 per million shown here is amongst the top rates
reported, along with 15 [14] and 21 per million [15] as
the highest. Compared to previous investigations on
MG epidemiology in Norway [16,17], our study sug-
gests an actual increase in MG occurrence, not only
because of better case identiﬁcation [6] and increased
recognition of the disease by GPs and neurologists but
also because of widespread AChR antibody testing [16].
High prevalence also reﬂects the reduced mortality [18].
A key factor inﬂuencing soaring incidence rates is the
ageing population, at higher risk of acquiring the dis-
ease [5].
Our data indicate that the increase in new cases of
drug requiring MG is chieﬂy because of the elderly.
Fifty-nine per cent of patients required treatment for
the ﬁrst time were ‡60 years and 38% were ‡70 years
old. In comparison, 44% of patients had MG onset
>65 years [12] and 46% >70 years [15] in two large
prospective studies, whereas onset ‡60 years in retro-
spective studies varies between 36% and 59%. A similar
age- and sex-speciﬁc incidence was shown in a study on
AChR-positive MG in the UK [19]. The relative highT
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incidence rates compared to prevalence are explained
by most patients with MG acquiring the disease in high
age. A real change in MG incidence, and especially in
the elderly, should be caused by unknown environ-
mental triggers. The immunological dissimilarities in
patients with early and late onset MG support that an
increase can occur in one and not in the other MG
subtype. Patients with late onset MG have lower titre of
circulating anti-AChR antibodies; antibodies to striated
muscle are more often found in late onset MG. HLA-
DR2 is frequently associated with late onset MG, in
contrast to early onset MG which is commonly asso-
ciated with HLA-DR3. Thymic hyperplasia rarely
occurs in late onset MG, and autoimmune co-morbidity
is more rare [20]. Most studies show similar modes of
onset as ours; bimodal for women and only one peak
for men [8,21]. This distinction conﬁrms diﬀerent gene–
environment interactions in early and late onset MG
[22].
Mean life expectancy for Norwegian women is
5 years longer than that for men, and there are slightly
more women ‡50 years in Norway than men. Still, the
late onset MG group comprised slightly more men than
women. Other investigators also report a small bias
towards men in late onset MG [23], establishing them as
more susceptible than women.
In the early onset MG group, a female predominance
was observed. The sex ratio in the Norwegian popula-
tion <50 years is nearly one. No evidence of terato-
genic eﬀects of pyridostigmine is documented and in
most cases symptomatic treatment is maintained also
during pregnancy [11]. Thus, women who temporarily
terminate the treatment of MG symptoms whilst preg-
nant have not caused bias to our incidence estimate,
also owing to the 3 years registration before recording
incidence. Provoking agents associated with MG onset
are seldom identiﬁable, and pregnancy and delivery
only accounted for one per cent in a recent survey [24].
Infections are known to potentially evoke MG symp-
toms [20]. Autoimmune disorders in general are more
common in women [25]. Women experience fatigue and
unspeciﬁed muscle weakness more often than men, and
Norwegian women are twice as likely to be tested for
AChR antibodies than men [16].
Myasthenia gravis was evenly geographically dis-
tributed in Norway, in contrast to what has been found
for multiple sclerosis (MS), with a lower disease fre-
quency in the northern region. Absolute MG preva-
lence and incidence numbers were lower in the north
also for MG, but this did not reach signiﬁcance. The
Sami population lives mainly in the north and has a low
MS prevalence [26]. The optimal case identiﬁcation
method assures minimal risk of regional selection bias.
Health care in Norway is nearly free of charge and
reimbursement regulations cover the drug costs for
chronic conditions. Our country also has one of the
worlds highest rates of practicing physicians per 1000
inhabitants, and neurologists are fairly evenly distrib-
uted in all ﬁve health regions.
Ninety per cent of all Norwegian patients with MG
are currently receiving symptomatic pyridostigmine
medication when comparing our data on active MG to
Heldal et al.s [16] estimated total MG prevalence of
145 per million in the same region and the same year.
Correspondingly, 10% should be in complete remission
or in pharmacologic remission with no need of pyri-
dostigmine. Estimates on remission rates from other
community-based studies vary from 12% to 20%
[27,28]. The low remission rate should be considered in
the light of 72% of our patients being late onset MG.
Early onset MG is more often associated with complete
stable remission [29]. To avoid bias in incidence esti-
mates because of relapsing cases, only new cases iden-
tiﬁed during the last year of the 4 year period were
included. Clinical remission lasting over 6–24 months is
considered to be stable [3]. Therefore, incidence over-
estimation because of relapses is likely to be small.
Norwegian Prescription Database is a nationwide
registry and provides a unique opportunity for epide-
miological research for diseases requiring speciﬁc
medication. The diagnosis is not available in NorPD,
but the indication for treatment with pyridostigmine
covered by reimbursement regulations is exclusive for
the MG diagnosis. However, in practice, pyridostig-
mine prescriptions to patients with LEMS or congenital
myasthenic syndromes will be reimbursed as for MG.
Also, ex juvantibus prescription and prescribing prac-
tice without proper reimbursement coding may theo-
retically occur, as may prescribing on non-MG
indications like gastrointestinal dysmotility in idio-
pathic pseudo-obstruction. But, because of the rarity of
this diagnosis and the inconclusive eﬀect of pyrido-
stigmine in these patients [30], we believe that by our
rigid criteria, the odds of including non-MG is small.
Conversely, the strict inclusion criteria might have
caused an underestimation of active MG. The 46
excluded patients did not diﬀer in drug dispensing from
the study population, nor in age and sex. Ten patients
were also prescribed corticosteroids, and two with
additional immunosuppressive medication. These
patients account for <10% of pyridostigmine recipi-
ents, and a misclassiﬁcation would not have altered our
conclusions signiﬁcantly.
Autoimmune MG is a potential life threatening but
treatable disorder. Diagnosis in the elderly is compli-
cated by higher degree of co-morbidity, and detection
of characteristic clinical signs like ptosis and muscle
weakness is more easily overlooked than in younger
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people [31]. Further epidemiological examinations on
seasonal trends in disease onset and exacerbation might
help establish a link between genetic susceptibility and
putative exogenous factors. The latitudinal range ren-
dering seasonal variety in climate and daylight expo-
sure, a long coastline and a conventional diet supplying
marine omega-3 polyunsaturated fatty acids make
Norway an ideal country for such research in addition
to a relatively homogenous population and high-quality
national registries. Our ﬁgures reﬂect a sensitive case
ﬁnding method, an ageing population and a high pre-
disposition for MG and autoimmune disease.
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Background and purpose: Comorbidity in myasthenia gravis (MG) is important for
diagnosis, treatment and prognosis. Disease complexity was assessed by examining
total drug treatment, immune therapy and comorbidity in a complete national MG
cohort.
Methods: All recipients of the MG-speciﬁc drug pyridostigmine 2004–2010 regis-
tered in the compulsory Norwegian Prescription Database who met the inclusion
criteria were included. The pyridostigmine group was compared with the general
Norwegian population.
Results: Myasthenia gravis patients received co-medication more often than the
controls for nearly all groups of medication, including insulins (95% conﬁdence
interval 2.0–3.7), thyroid therapy (1.7–2.5), antidepressants (1.3–1.7), anti-infectives
(1.2–1.4), lipid-modifying agents (1.1–1.4) and immunomodulating agents (6.8–8.8).
Conclusions: Myasthenia gravis patients are more often treated with non-MG pre-
scription drugs than controls, reﬂecting frequent co-medication and comorbidity.
Introduction
Autoimmune myasthenia gravis (MG) is mainly
caused by the destruction of acetylcholine receptors
by autoantibodies at the neuromuscular junction. MG
is a heterogeneous disease with several subtypes and
autoantibodies against skeletal muscles [1]. Life expec-
tancy for MG patients is now near normal [2], but
management of a ﬂuctuating disease remains challeng-
ing. New therapeutic options are emerging, and MG
subtype classiﬁcation has implications for treatment
strategies [3].
The task of controlling symptoms whilst minimizing
adverse eﬀects of long-term immunosuppressive treat-
ment is intricate. Furthermore, the clinical implica-
tions of heart muscle antibodies, involvement of
respiratory function in MG and use of drugs that may
worsen neuromuscular blockade have not been widely
studied, nor have autoimmune comorbidity and psy-
chiatric disorders been described in unselected MG
cohorts. Our study provides a national cohort for
evaluating the total drug management of symptomatic
MG, oﬀering a new insight into the total disease bur-
den for this group.
The aims of the study were to evaluate drug treat-
ment and thereby also comorbidity in patients with
MG. First, an overview is given of the overall
national drug consumption amongst MG patients.
Secondly, MG autoimmune comorbidity is assessed
through co-medication. Thirdly, psychiatric disorders
in MG are explored through speciﬁc drug treatment.
Fourthly, prescription practice is investigated with
regard to selected drugs considered as relatively con-
traindicated in MG. Finally, ﬁrst- and second-line
drug treatment of MG is investigated.
Methods
Registration of all prescription drugs dispensed from
Norwegian pharmacies in the Norwegian Prescription
Database (NorPD) has been mandatory since 2004,
covering the entire Norwegian population (5 096 300).
A unique personal identiﬁer enables consecutive moni-
toring of individuals in the health system over their
entire life span. The speciﬁc diagnosis or indication
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for the prescription is not registered in NorPD, but
the International Classiﬁcation of Diseases, 10th revi-
sion (ICD-10), and/or the International Classiﬁcation
of Primary Care, 2nd edition (ICPC-2), have been
recorded since 2008. Medication for chronic diseases
such as MG is reimbursed. The reimbursement codes
together with the ICD-10 and ICPC-2 codes function
as a proxy of diagnosis. The following variables were
studied: the patient’s year of birth and sex, the pre-
scriber’s medical speciality, reimbursement codes,
ICD-10/ICPC-2 codes, name of the drug, Anatomical
Therapeutic Chemical (ATC) code, date of expedition
at the pharmacy, and the deﬁned daily dose (DDD)
of the drugs dispensed. In NorPD, the DDD corre-
sponds to the assumed mean maintenance dose of the
drug used per day for its main indication in adults [4].
About 890 individuals with at least one prescription
of pyridostigmine from 1 January 2004 to 30 April
2010 were identiﬁed. Amongst these, 830 (93%) met
one or more of the criteria preset by us to conﬁrm a
diagnosis of MG and were regarded as having MG:
(i) ≥2 prescriptions of pyridostigmine during the study
period; (ii) pyridostigmine prescription made by a
neurologist; (iii) pyridostigmine prescription with
reimbursement code (§13) or ICD-10 code (G70.0)/
ICPC-2 code (N99) speciﬁc for MG (Fig. 1). Final
inclusion for this study was done from the date when
one or more of the criteria were fulﬁlled. Sensitivity
analyses with more stringent inclusion criteria to test
the robustness of our study population were per-
formed (Table S1).
For each subgroup of patients categorized by age
and sex, drug statistics for the corresponding age and
sex groups in the Norwegian population registered in
NorPD from the same period functioned as controls
(Table 1). Total drug treatment of MG patients was
assessed by investigating every prescription dispensed
in all main ATC groups during the study period.
Comparisons of age- and sex-speciﬁc drug use
amongst MG patients and controls were done by cal-
culating the standardized incidence ratio (SIR), i.e.
the observed number of prescriptions for all main
ATC groups divided by the estimated number of pre-
scriptions for the same drug groups dispensed to a
similar group, with regard to age and sex, in the gen-
eral population. Patient age was deﬁned as age at 1
July 2004. The SIR was computed, with 95% conﬁ-
dence interval (CI), assuming a Poisson distribution.
The ATC group ‘Various’ was considered non-speciﬁc
and was excluded from the analyses.
When exploring comorbidities and contraindicated
medications, the following groups of drugs were
included: drugs used in diabetes, insulins and
analogues, thyroid hormones, antipsychotics, anxiolyt-
ics, hypnotics and sedatives, antidepressants, antiepi-
leptics, beta-blocking agents, calcium-channel
blockers, lipid-modifying agents and aminoglycoside
antibacterials. The following groups of immunomo-
dulating agents were assessed: prednisolone, selective
immunosuppressants, tumor necrosis factor alpha
inhibitors, interleukin inhibitors, calcineurin inhibi-
tors, and other immunosuppressants.
To detect any diﬀerences in prescription of ATC
groups related to age and sex, linear regressions were
performed, estimating the mean diﬀerence and 95%
CIs. Two-sided P values ≤ 0.05 were considered
Recipients of pyridostigmine 
1 January 2004 – 30 April 2010: 
890 
Excluded*: 
60 (7%)
MG study population: 
830  
MG women:
527 (63%)
MG men: 
303 (37%)
Figure 1 Selection of the MG study cohort. *Recipients of pyri-
dostigmine who did not meet the inclusion criteria during the
study period.
Table 1 Demographic characteristics of the study population and
population controls, year 2004
MG patients
(n = 830)
Population controls
(n = 4 577 457)
Age (mean)a 57 39
Sex (n, %)
Female 527 (64) 2 269 049 (50)
Male 303 (37) 2 308 408 (50)
Age group (n, %)
0–9 3 (0.4) 598 503 (13)
10–19 29 (4) 591 853 (13)
20–29 36 (4) 570 889 (13)
30–39 105 (13) 698 413 (15)
40–49 97 (12) 639 053 (14)
50–59 148 (18) 595 423 (13)
60–69 159 (19) 374 975 (8)
70–79 175 (21) 299 162 (7)
80–89 67 (8) 180 640 (4)
> 90 11 (1) 28 546 (0.6)
aPatient age was calculated from year of birth and deﬁned as age at
1 July 2004.
© 2014 The Author(s)
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statistically signiﬁcant. The median DDD prescribed
each year was compared for pyridostigmine and for
each of the following immunomodulating agents:
prednisolone, azathioprine, mycophenolic acid, cyclo-
sporine and methotrexate, as recommended by the
European Federation of Neurological Societies guide-
lines for MG treatment [5]. Non-parametric tests were
performed for comparisons regarding amount dis-
pensed between age and sex groups. IBM SPSS Statis-
tics for Windows, version 20.0 (IBM Corp., Armonk,
NY, USA), and Microsoft Excel were used in all sta-
tistical analyses. Ethics committee approval is not
required for studies using anonymous data retrieved
from central health registers.
Results
In total, 87 556 prescription medications were dis-
pensed to the 830 MG patients during the registration
period (Table 2). The mean number of new ATC
groups per year is shown in Table S2. Only 19 individu-
als (2.3%) received no other medication than pyrido-
stigmine. MG patients more often received nearly all
types of medication compared with the control group,
most pronounced for the following treatment groups:
alimentary tract and metabolism (A); systemic hor-
monal preparations, excluding sex hormones and insu-
lins (H); antineoplastic and immunomodulating agents
(L). Patients <50 years received fewer ATC groups than
patients ≥50 years and women received fewer than
men, but neither of the diﬀerences was signiﬁcant.
Insulins were almost three times more frequently
prescribed to MG patients (95% CI 2.0–3.7, Table 3)
compared with controls. This was observed for MG
patients ≥50 years (1.9–3.7), for men (1.7–4.3) and for
women (1.7–4.0). MG patients <50 years also had
increased prescriptions of insulins (SIR = 2.8), but
there were too few users to provide suﬃcient statisti-
cal power (N = 5). A hundred and ten MG patients
(13%) received a prescription of thyroid hormones.
Thyroid hormones were prescribed about four times
more frequently to MG patients <50 years (2.4–5.5)
and male MG patients (2.3–5.0). Patients ≥50 years
and female MG patients received thyroid hormones
about twice as often compared with controls (1.5–2.2
and 1.4–2.2, respectively).
In all, 29% of MG patients received treatment with
hypnotics and sedatives, and such drugs were twice as
often given to MG patients than to controls for the
age group <50 years (1.2–2.3). 21% received antide-
pressants, twice as often given to male MG patients
than to male controls (1.3–2.2). For the remaining age
and sex groups, slightly more MG patients than con-
trols were treated with hypnotics, sedatives and an-
tidepressants. 20% received anxiolytics, whilst 7%
received antipsychotics (Table 3). Anxiolytics and
antipsychotics were prescribed to MG patients and
controls with the same frequency.
Myasthenia gravis patients were twice as often trea-
ted with antiepileptic drugs (1.7–2.5). They were also
more frequently treated with calcium-channel blockers
(1.2–1.7) and lipid-modifying agents (1.1–1.4), but
with the same frequency as in the controls with beta-
blocking agents (0.9–1.2). All four drug groups were
given more frequently to MG patients <50 years
compared with controls at the same age (Table 3).
However, the number of users of calcium-channel
blockers, lipid-modifying agents and beta-blocking
agents was too low to provide enough statistical
power (N = 6, 11, 11 respectively).
The DDDs of pyridostigmine were signiﬁcantly
lower for MG patients <50 years compared with those
≥50 years (P < 0.001). There was no diﬀerence
between men and women (P = 0.8). Immunomodulat-
ing agents were prescribed less to patients <50 years
(P < 0.001) and women (P = 0.001) compared with
patients ≥50 years and men (Table 4); 406 MG
patients (49%) had no immunomodulating agents
expedited during the study period. The mean number
of new groups of immunomodulating agents used per
year was not signiﬁcantly diﬀerent between the two
age and sex groups (P = 0.2 and P = 0.9, respectively;
Fig. 2a and b). Regression analyses with mutual
adjustment for age and sex did not alter the diﬀer-
ences regarding age and sex.
Signiﬁcantly fewer DDDs of prednisolone was pre-
scribed to patients <50 years compared with patients
≥50 years (P < 0.001). No age diﬀerence was seen for
azathioprine (P = 0.1). Women were prescribed signif-
icantly fewer DDDs of prednisolone (P < 0.001) and
azathioprine (P = 0.002) than men. For mycophenolic
acid, cyclosporine and methotrexate, the number of
users and DDDs prescribed were too small to be
included in the calculations.
Discussion
This is the ﬁrst study to assess the total drug man-
agement and comorbidity of MG in a complete
national cohort. Our ﬁndings show that co-medica-
tion in MG is widespread, requiring more frequent
drug treatment for several major disease groups than
in the general population. Treatment for diabetes,
thyroid disease and psychiatric disorders in MG is
common, as well as co-medication relatively contrain-
dicated in MG. These ﬁndings demonstrate the exten-
sive disease burden of MG and the complexity of the
disease.
© 2014 The Author(s)
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Increased treatment frequency with drugs for the
cardiovascular system in MG patients younger than
50 years was found. Arguably, there is a risk of
ascertainment bias as MG patients more regularly
visit a physician. However, physical inactivity due to
muscle weakness, side eﬀects of steroid treatment
such as weight gain and elevated blood glucose levels
are factors that may contribute to the increased risk
of cardiovascular disease, even in younger individu-
als. The possibility for cardiac involvement in MG is
also well recognized [6], although death caused by
cardiac diseases is not increased [2]. The clinical
implications remain unclear [7], but our data strongly
indicate that there is a clinically relevant association
between MG and cardiovascular disease. Early treat-
ment of airway infections in MG patients is recom-
mended [3], and may account for the increased use of
anti-infectives. Immunosuppressed patients are also
in general more prone to infections [5].
In this study, thyroid hormones were most fre-
quently prescribed to MG patients <50 years and to
men compared with controls. A recent systematic
review estimated concomitant autoimmune diseases in
MG at 13%, with thyroid disease as the most fre-
quent [8]. In prospectively identiﬁed MG patients,
type 1 and 2 diabetes was found in 10% and 8%,
respectively [9]. All antidiabetics in our study were
most frequently prescribed to patients ≥50 years. In
addition to the general autoimmune disease overlap,
reduced physical activity, corticosteroid treatment as
well as other comorbid conditions may serve as
catalysts for acquired metabolic syndrome and type 2
diabetes.
Use of antidepressants was more frequent amongst
MG patients than controls. The frequency of patients
receiving antidepressants in our study is in good
agreement with previous reports of aﬀective disorders
in MG [10]. Drug treatment of anxiety and sleep dis-
turbances was lower in our study compared with pre-
vious reports [11,12]. Psychiatric symptoms can mimic
MG symptoms, but may also be under-recognized due
to overlapping symptoms [13].
Age ≥50 years and male sex were predictors for
immunosuppressive treatment in our study. Immuno-
suppressive drugs and thymectomy represent the main
principles in treating moderate to severe MG [3], often
lifelong in late-onset and thymoma cases (15% of MG
patients). Complete stable remission can be induced in
early-onset cases after thymectomy. The beneﬁt of thy-
mectomy for MG symptom relief is questionable for
late-onset MG and thymoma MG patients [14]. Only
56% of the patients in our study over 50 years were
treated with immunoactive drugs. Some muscle weak-
ness is probably under-recognized in older patients due
to the aging process or concomitant illness. One recent
hospital-based study reported immunosuppressive ther-
apy in 65% of late-onset cases [15]. In our study early-
and late-onset cases were combined in the group above
50 years. A biological explanation implicating diﬀer-
ences in disease severity is possible, but inadequate
immunosuppression in our patients is also highly prob-
able. Teratogenic and other adverse eﬀects inﬂuence
immunosuppressive treatment in young females. Such
drugs are rarely used in pregnancy [16].
Only 6% of all MG patients in our study had such
a severe disease that second-line immunomodulating
drugs were required, indicating that prednisolone and
azathioprine alone or in combination are suﬃcient for
symptom control in nearly all MG patients. NorPD
does not provide information on other treatment
modalities, such as thymectomy, plasma exchange and
intravenous administration of immunoglobulins.
Patients identiﬁed with severe MG were predomi-
nantly ≥50 years old and females. MuSK-MG is more
often seen in females and is associated with more
severe disease, but this MG subtype is very rare in
Norway [17]. Information on MG subtypes is not
available in the NorPD.
The main strength of our study is case ascertain-
ment from one single, unbiased, comprehensive
Table 4 Number of MG patients using selected immunomodulating drugs with comparisons of DDDs prescribed, 2004–2010
Women
(n = 527)
Men
(n = 303)
<50 years
(n = 270)
≥50 years
(n = 560)
ATC group  Drug n (%) n (%) P valuea n (%) n (%) P valuea
H02AB06  Prednisolone 220 (42) 167 (55) <0.001 102 (38) 285 (51) 0.001
L04AX01  Azathioprine 109 (21) 92 (30) 0.002 56 (21) 145 (26) 0.12
L04AA06  Mycophenolic acid 16 (3) 7 (2) NA 8 (3) 15 (3) NA
L04AD01  Cyclosporine 11 (2) 4 (1) NA 7 (3) 8 (0.1) NA
L04AX03  Methotrexate 9 (2) 1 (0.3) NA 3 (0.1) 7 (0.1) NA
All immunosuppressants 246 (47) 178 (59) 0.001 113 (42) 311 (56) <0.001
NA, not available or insuﬃcient data available for analysis. aNon-parametric tests were used to calculate the diﬀerence in median deﬁned daily
dose between sex and age groups in the period 2004–2010.
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database with a full, national population as controls.
96% of the entire Norwegian population has been
included in NorPD since its establishment in 2004
with at least one prescription drug dispensed from a
pharmacy. The 1 year prevalence of 68%–69% of the
population in NorPD has proven stable [18]. Identi-
fying MG patients by prescriptions of pyridostigmine
is considered sensitive with a high positive predictive
value for the diagnosis [19–21], and with good agree-
ment of calculated prevalence rates using pyridostig-
mine prescriptions registered in the NorPD compared
with rates calculated from a nationwide acetylcholine
receptor antibody database [22]. Amongst 67 patients
treated at our department for the past 30 years, only
three did not receive pyridostigmine (unpublished
data). NorPD did not include indication for prescrip-
tion until 2008. This represents a potential source of
overestimation. The inclusion criteria used in this
study secured high sensitivity, although speciﬁcity
may be lower. However, sensitivity analyses with
more stringent criteria did not alter the basic charac-
teristics of the MG cohort. Moreover, nearly 90% of
our study population had conﬁrmed at least one
MG-reimbursed prescription of pyridostigmine or
from a neurologist. Only MG patients with a con-
ﬁrmed diagnosis are given reimbursement. The reim-
bursement code is therefore highly speciﬁc for MG.
Pyridostigmine is not prescribed on a regular basis to
any other disease groups. The rare disease Lam-
bertEaton myasthenic syndrome, with a prevalence
of 2–3 per million [23], is treated with pyridostigmine
and reimbursement would be given as for MG. Six
patients with pyridostigmine were identiﬁed with an
additional prescription of ﬂudrocortisone, the stan-
dard drug for treating orthostatic hypotension, and
may marginally bias our ﬁndings.
This study reveals the true complexity of MG and
contributes to an understanding of the impact of MG
on health. Awareness of comorbidities and knowledge
of treatment practice should help physicians in choos-
ing the best treatment strategy.
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Figure 2 (a) Mean number of new groups of immunomodulat-
ing agents used in MG patients (%) below and above
50 years of age after MG diagnosis per year, 2004–2010. Open
bars, patients <50 years; hatched bars, patients ≥50 years. (b)
Mean number of new groups of immunomodulating agents
used in MG men and women (%) after MG diagnosis per
year, 2004–2010. Open bars, men; hatched bars, women.
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Table S1. Characteristics of the study population with
diﬀerent inclusion criteria.
Table S2. Mean (SD) number of new ATC groups for
830 MG patients per year, 2004–2010.
References
1. Querol L, Illa I. Myasthenia gravis and the neuromuscu-
lar junction. Curr Opin Neurol 2013; 26: 459–465.
2. Owe JF, Daltveit AK, Gilhus NE. Causes of death
among patients with myasthenia gravis in Norway
between 1951 and 2001. J Neurol Neurosurg Psychiatry
2006; 77: 203–207.
3. Gilhus NE, Owe JF, Hoﬀ JM, et al. Myasthenia gravis:
a review of available treatment approaches. Autoimmune
Dis 2011; 2011: 847393.
4. WHO Collaborating Centre for Drug Statistics Method-
ology. Norwegian Institute of Public Health Guidelines
for ATC classiﬁcation and DDD assignment. Oslo, Nor-
way, 2005.
5. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for
treatment of autoimmune neuromuscular transmission
disorders. Eur J Neurol 2010; 17: 893–902.
6. Mygland A, Aarli JA, Hofstad H, Gilhus NE. Heart
muscle antibodies in myasthenia gravis. Autoimmunity
1991; 10: 263–267.
7. Owe JF, Skulstad Davidsen E, Eide GE, Gerdts E,
Gilhus NE. Left ventricular long-axis function in myas-
thenia gravis. J Neurol 2008; 255: 1777–1784.
8. Mao ZF, Yang LX, Mo XA, et al. Frequency of auto-
immune diseases in myasthenia gravis: a systematic
review. Int J Neurosci 2011; 121: 121–129.
9. Toth C, McDonald D, Oger J, Brownell K. Acetylcho-
line receptor antibodies in myasthenia gravis are associ-
ated with greater risk of diabetes and thyroid disease.
Acta Neurol Scand 2006; 114: 124–132.
10. Ybarra MI, Kummer A, Frota ER, et al. Psychiatric
disorders in myasthenia gravis. Arq Neuropsiquiatr 2011;
69: 176–179.
11. Lundeen J, Fisher J, Kothari MJ. Frequency of anxiety in
myasthenia gravis. J Clin Neuromuscul Dis 2004; 6: 9–12.
12. Martinez De Lapiscina EH, Aguirre ME, Blanco TA,
Pascual IJ. Myasthenia gravis: sleep quality, quality
of life, and disease severity. Muscle Nerve 2012; 46:
174–180.
13. Kulaksizoglu IB. Mood and anxiety disorders in patients
with myasthenia gravis: aetiology, diagnosis and treat-
ment. CNS Drugs 2007; 21: 473–481.
14. Romi F, Gilhus NE, Varhaug JE, et al. Thymectomy and
antimuscle antibodies in nonthymomatous myasthenia
gravis. Ann N Y Acad Sci 2003; 998: 481–490.
15. Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia
gravis in the elderly. J Neurol Sci 2013; 325: 1–5.
16. Hoﬀ JM, Daltveit AK, Gilhus NE. Myasthenia gravis in
pregnancy and birth: identifying risk factors, optimising
care. Eur J Neurol 2007; 14: 38–43.
17. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia
gravis: disease severity and prognosis. Eur J Neurol
2005; 12: 413–418.
18. Norwegian Institute of Public Health. Norwegian Pre-
scription Database 2007–2011. Oslo, Norway, 2012.
19. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D.
Identifying patients with myasthenia for epidemiological
research by linkage of automated registers. Neuroepidem-
iology 2011; 37: 120–128.
20. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myas-
thenia gravis requiring pyridostigmine treatment in a
national population cohort. Eur J Neurol 2010; 17:
1445–1450.
21. Gattellari M, Goumas C, Worthington JM. A national
epidemiological study of myasthenia gravis in Australia.
Eur J Neurol 2012; 19: 1413–1420.
22. Andersen JB, Heldal AT, Engeland A, Gilhus NE.
Myasthenia gravis epidemiology in a national cohort;
combining multiple disease registries. Acta Neurol Scand
2014; 129 (Suppl. 198): 26–31.
23. Titulaer MJ, Lang B, Verschuuren JJ. LambertEaton
myasthenic syndrome: from clinical characteristics to
therapeutic strategies. Lancet Neurol 2011; 10: 1098–1107.
© 2014 The Author(s)
European Journal of Neurology © 2014 EAN
Total drug treatment in myasthenia gravis 955
 
 
 
 
 
Supplemental Material Paper II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1. Characteristics of the study population with different inclusion criteria.
A 890 57 (19) 565 (63)
B 830 57 (18) 527 (63)
C 782 57 (19) 495 (63)
D 791 57 (19) 500 (63)
E 726 58 (19) 455 (63)
F 660 58 (19) 422 (64)
A = All recipients of pyridostigmine from January 1st 2004 – April 30th 2010.
C = All recipients of pyridostigmine who fulfilled criteria 3 and 4. 
D = All recipients of pyridostigmine who fulfilled criteria 2, 3 and 4.
E = All recipients of pyridostigmine who fulfilled criteria 2 and 3.
F = All recipients of pyridostigmine who fulfilled criteria 3 only.
Definition Number of MG patients 
Number of female 
MG patients (%)
Mean age of MG 
patients (sd)
B = All recipients of pyridostigmine who fulfilled either of the following inclusion criteria: 1) ≥2 
pyridostigmine prescription, 2) one prescription of pyridostigmine made by a neurologist, 3) one 
prescription of pyridostigmine with a reimbursement code specific for MG (§13), 4) one prescription 
of pyridostigmine with an ICD-10 code (G70.0) or ICPC-2 code (N99) specific for MG.
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